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Deposition of amyloid-β (Aβ) is 
considered to be a key element in the 
pathogenesis of Alzheimer’s disease 
(AD). In this study no association 
between Aβ deposition and cere-
brovascular disease, diabetes, alco-
hol abuse and synucleinopathy was 
found, a finding that is at odds with 
proposal that these alterations are 
risk factor for AD via Aβ deposition. 
The strong association between age 
and Aβ deposition indicates that the 
age-related changes are significant 
for the accumulation of Aβ. The role 
of Aβ deposits remains open - are 
they harmful, inert, or protective? 
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ABSTRACT 
 
With the aging population, neurodegenerative diseases are becoming major and extremely expensive health 
problems. The pathological cascade leading to neuronal death encountered in neurodegenerative diseases is still 
unclear, making the development of curative treatments challenging. Alteration in amyloid-β (Aβ) metabolism and 
ultimately in the deposition of Aβ is considered to be a key element in the pathogenesis of the most common age-
related neurodegenerative disorder, Alzheimer’s disease (AD). However, Aβ deposits are also seen in the brains of 
elderly cognitively intact subjects and a recent finding indicated that Aβ plaque removal does not prevent the 
progressive neurodegeneration challenging the presumption that Aβ represent the key factor in the 
ethiopathogenesis of AD. The deposition of Aβ in the brain parenchyma is however strongly linked with AD, and 
thus the risk factors for AD found in epidemiological studies have also been considered to be linked with the 
accumulation of Aβ. 
The purpose of the present study was to investigate the proposed associations between Aβ deposition and 
cerebrovascular disease, diabetes, alcohol abuse and concomitant α-synuclein pathology in a large autopsy sample 
(n=1720) applying immunohistochemical methodology. The study cohort included both symptomatic and 
neurologically unimpaired subjects who had been autopsied which included a neuropathological examination in 
the Kuopio University Hospital. 
The prevalence of cortical Aβ deposition varied from 19 to 60 % in the subjects in the different study groups. 
The prevalence of extracellular Aβ increased with age but the influence of gender was not entirely clear. Risk factors 
such as cerebrovascular disease, diabetes, and alcohol abuse did not have any influence on the accumulation of 
extracellular Aβ. Moreover, Aβ, HPτ and αS pathology were commonly seen concomitantly in elderly individuals.  
The present study confirms that a substantial proportion of cognitively intact elderly individuals display 
extracellular Aβ in their cortical regions. Cerebrovascular disease, diabetes, or alcohol abuse had no influence on the 
deposition of Aβ, a finding that is at odds with proposal that these alterations are risk factor for AD via Aβ 
deposition. The strong association between age and the prevalence of Aβ deposition may indicate that the age-
related changes in the formation and elimination of Aβ are significant for the accumulation of Aβ. The observed 
regular co-occurrence of all three studied age-related pathologies, i.e. Aβ, HP and αS does not necessarily indicate 
that one alteration is caused by one of others. These findings question the assumption that Aβ deposition is the 
initiator of the pathological cascade leading to neuronal death. Thus, the question of role of extracellular and 
intracellular Aβ aggregates is still open; are they harmful, inert, or protective? 
 
National Library of Medicine Classification: WL359; QZ140; WH400 
 
Medical Subject Headings (MeSH): Alcoholism; Alzheimer disease; Amyloid beta-Protein; Autopsy; 
Cerebrovascular Disorders; Diabetes Mellitus; Humans; Immunohistochemistry; Neurodegenerative diseases 
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TIIVISTELMÄ 
 
Rappeuttavat aivosairaudet lisääntyvät voimakkaasti väestön ikääntyessä, ja ovat yksi yhteiskuntamme kalliista 
kansantaudeista. Rappeuttavien aivosairauksien etiologia ja patogeneesi ovat edelleen epäselviä, minkä vuoksi 
parantavan hoidon kehittäminen on haastavaa.  Yleisin rappeuttava aivosairaus on Alzheimerin tauti (AT), jonka 
neuropatologisia tunnusmerkkejä ovat amyloid-β-proteiini (Aβ) ja hyperfosforyloitunut-τ (HPτ). Aβ:n kertymisen 
solun ulkopuolelle on arveltu laukaisevan tapahtumaketjun, joka johtaa hermosolujen vaurioitumiseen ja 
solukatoon. Suuret väestöpohjaiset tutkimukset ovat kuitenkin osoittaneet, että osalla oireettomista ikääntyneistä 
nähdään merkittäviä määriä Aβ:n kertymiä aivoissa, ja toisaalta Aβ:n määrä aivoissa ei korreloi oireiden vaikeuden 
kanssa. Nämä tulokset kyseenalaistavat yksinkertaisen syy-seuraussuhteen Aβ:n kertymisen ja kliinisten oireiden 
välillä.  
Epidemiologisissa ja eläintutkimuksissa on todettu aivohalvauksen, diabeteksen ja runsaan alkoholin käytön 
kasvattavan rappeuttavan aivosairauden riskiä lisäämällä Aβ:n kertymistä aivoihin. Tämän tutkimuksen 
tavoitteena oli arvioida esitettyjen riskitekijöiden vaikutusta Aβ:n kertymiseen aivoihin ihmisillä. Ikääntyneillä 
esiintyy aivoissa usein samanaikaisesti Aβ:n ja HPτ:n lisäksi myös α-synukleiinia (αS), mutta näiden patologioiden 
keskinäinen vaikutus toisiinsa on epäselvä.  Työn toisena tavoitteena oli arvioida Aβ:n, HPτ:n ja αS:n keskinäisiä 
vaikutuksia toisiinsa. Tutkimusmateriaali koostuu yhteensä 1720 oireettomasta ja dementoituneesta henkilöstä, 
joille on tehty ruumiinavaus ja neuropatologinen tutkimus Kuopion yliopistossa. Metodina käytettiin 
immunohistokemiaa. 
Tutkimuksessa havaittiin Aβ:n kertymiä aivokuorella valintakriteereistä riippuen 19–60 %:lla tutkituista. Aβ:n 
esiintyminen korreloi voimakkaasti iän kanssa, mutta sukupuolen vaikutus ei ollut yhtä selvä. Aivohalvaus, 
diabetes tai runsas alkoholin käyttö eivät vaikuttaneet Aβ:n esiintymiseen. Ikäihmisillä nähtiin aivoissa usein 
kaikkia kolmea patologiaa, Aβ:ta, HPτ:ta ja αS:a. 
Nämä tulokset vahvistavat, että suurella joukolla oireettomista ikääntyneistä on Aβ-kertymiä aivoissa. 
Aivohalvaus, diabetes tai runsas alkoholin käyttö eivät näytä lisäävän Aβ:n määrää aivoissa, mikä kyseenalaistaa 
hypoteesin, että nämä kliiniset tilat lisäisivät dementian riskiä vaikuttamalla Aβ:n aineenvaihduntaan. Voimakas 
korrelaatio Aβ:n esiintymisen ja iän välillä viittaa, että ikääntymiseen liittyvät muutokset Aβ:n tuotossa ja 
eliminaatiossa ovat tärkeitä Aβ:n kertymiselle. Aβ:n, HPτ:n ja αS:n yhdenaikainen esiintyminen aivoissa ei 
välttämättä viittaa siihen, että ne ovat suorassa syy-seuraussuhteessa toisiinsa. Nämä tulokset kyseenalaistavat 
oletuksen, että Aβ on laukaiseva tekijä, joka aloittaa hermosolujen kuolemaan johtavan tapahtumaketjun. Aβ:n rooli 
ja merkitys rappeuttavissa aivosairauksissa on edelleen epäselvä; ovatko Aβ-kertymät haitallisia, haitattomia vai 
suojelevia.    
 
Luokitus: WL359; QZ140; WH400 
 
Yleinen suomalainen asiasanasto (YSA): aivosairaudet; aivoverenkiertohäiriöt; alkoholinkäyttö; amyloidi; diabetes; 
ihminen; ruumiinavaus 
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1 Introduction 
 
The proportion of elderly people is increasing as the increase in human 
lifespan increases the susceptibility to live long enough to suffer 
neurodegenerative disorders (Jagger et al., 2007). This increase in the 
incidence of neurodegenerative disorders is responsible for social and 
economical cost for public health and as well individual suffering 
(Gorshow, 2007). Alzheimer’s disease (AD) is the best known old age 
associated disease affecting millions of individuals in the Western 
countries and it is one of the leading causes of death in the elderly 
population (Heron and Smith, 2007; Lobo et al., 2000). The pathogenesis 
of AD is still unclear and there is no curative treatment available, and 
therefore it is still essential to examine the underlying mechanisms of 
AD. 
The neuropathological diagnosis of AD is based on the detection of 
two hallmark proteins, amyloid-β (Aβ) and hyperphosphorylated-τ 
(HPτ), in the neuropathological examination (Braak and Braak, 1997). 
For decades, the extracellular accumulation of Aβ has been considered 
as the trigger for eliciting a cascade leading to neuronal dysfunction 
and death in AD.  However, the role and function of Aβ are still under 
debate, as some researchers believe that Aβ has a physiological 
function, others believe that Aβ is an acute phase protein, and finally 
many researchers are convinced of the validity of the amyloid cascade 
hypothesis of AD (Haass et al., 1992; Hardy and Allsop, 1991; Jendroska 
et al., 1995). It is noteworthy that a substantial proportion of elderly 
population displays extracellular Aβ without expressing any 
neurological or psychiatric symptoms, indicating that the accumulation 
of Aβ is an age-related phenomenon (Bennett et al., 2006; Davis et al., 
1999; MRC CFAS, 2001; Snowdon, 1997).   
In addition to aging, epidemiological and experimental animal 
studies have observed some connection between the accumulation of 
Aβ and general diseases such as stroke, diabetes and alcohol abuse. It 
has been suggested that ischemic stress caused by stroke or toxic stress 
caused by alcohol abuse, or the metabolic alteration which accompany 
diabetes may increase the load of extracellular Aβ and consequently 
play a role in neurodegeneration. However, in human post-mortem 
studies, the association between Aβ and these proposed conditions has 
been far from clear (Arvanitakis et al., 2004; Janson et al., 2004; Paula-
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Barbosa and Tavares, 1984; van Groen et al., 2005). One explanation for 
discrepant results is that there are physiological differences between 
humans and animals that impact on all studies that use animals as a 
model for human biology, and thus it is essential to re-evaluate the 
findings obtained from animal studies with human material (Odom et 
al., 2007).  
Access to a large autopsy material including diseased and healthy 
individuals provided a unique opportunity to investigate the putative 
connection between the accumulation of Aβ and the proposed risk 
factors, and to assess the clinical relevance of Aβ pathology in human 
brains by applying immunohistochemical methods.  
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2 Review of the literature 
 
2.1 AMYLOID β-PROTEIN 
 
2.1.1 Historical aspects of Aβ 
Alois Alzheimer, a German psychiatrist, was the first to describe 
neuropathological findings of Alzheimer’s disease (AD). In 1906, he 
examined a 51-year old woman with a five year history of progressive 
memory impairment. When he autopsied her brain, Alois Alzheimer 
detected neurofibrillary tangles in nerve cells and senile plaques all 
over the cerebral cortex while applying the silver impregnation method 
(Alzheimer, 1907; for review Jellinger, 2006a). Later, these two lesions 
have been recognized as the hallmark lesions of AD.  In 1984, Glenner 
and Wong isolated a 4200 dalton polypeptide, Aβ from amyloidotic 
vessels of Alzheimer disease and Down Syndrome patients (Glenner 
and Wong, 1984a) and one year later Masters and co-workers found the 
same polypeptide Aβ in senile plaques (Masters et al., 1985) and finally 
in the late 1980’s Aβ was also reported to be seen in intracellular 
compartments in human brain (Grundke-Iqbal et al., 1989).  
 
2.1.2 Structure and formation of Aβ 
Aβ is a hydrophobic, self-aggregating peptide consisting of 40-43 amino 
acids and it is a cleavage product of the larger transmembrane amyloid 
precursor peptide (APP), encoded as a single-copy gene on 
chromosome 21 (Glenner and Wong, 1984a; Haass et al., 1992; Masters 
et al., 1985; Tanzi et al., 1988).  APP with unknown function consists of 
695-770 amino acids, and it is widely expressed in the brain (Kinoshita 
et al., 2003). The cleavage of APP has been reported to occur, when APP 
is located to the plasma membrane, endoplasmic reticulum, endosomal 
and lysosomal membranes (Kinoshita et al., 2003), trans-Golgi network  
(Xu et al., 1995) and mitochondrial membrane (Mizuguchi et al., 1992).  
The cleavage of APP can be divided into a non-amyloidogenic and an 
amyloidogenic pathway as demonstrated in figure 1.  In the non-
amyloidogenic pathway, APP is cleaved by the α-secretase and 
subsequently by the γ-secretase within the Aβ domain which leads to 
the formation of a 16 amino acid shorter peptide termed P3 (Bayer et 
al., 2001; Kojro and Fahrenholz, 2005). This is the major processing 
pathway in most cell types. In the amyloidogenic pathway, Aβ peptide 
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is cleaved from APP by two sequential enzymatic activities. The initial 
cleavage is mediated by the β-secretase identified as the novel aspartyl 
protease (Evin and Weidemann, 2002). This cleavage results in the 
release of sAPPβ into the extracellular space leaving a fragment called 
C99 within the membrane. The final cleavage is mediated by γ-
secretase, a multimeric complex containing presenilins, which releases 
Aβ peptide (Evin and Weidemann, 2002).  Soon after generation of Aβ, 
the peptide is secreted from the cell into the extracellular pool (Walsh et 
al., 2002). Most of the produced Aβ is 40 residues in length (Aβ40) and 
it is generated solely within the transgolgi network (Xu et al., 1995). 
Approximately 10 % of Aβ are 42 residues in length (Aβ42) and this 
form is generated in the endoplasmic reticulum and transgolgi network 
(Greenfield et al., 1999). The Aβ42 residue is more hydrophobic and in 
vitro it polymerizes into fibrils more readily than the Aβ40 residue 
(Bitan et al., 2003; Jarrett et al., 1993). This longer form is the 
predominant component in parenchymal plaques (Younkin, 1998) and 
generally Aβ42 is considered to be more toxic than Aβ40, whereas Aβ40 
is a major form under physiological conditions (Bitan et al., 2003; Jarrett 
et al., 1993). However, this is controversial, as both in vitro and in vivo 
studies have reported that Aβ40 aggregates are also toxic (Walsh et al., 
2002).  
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Figure 1. APP proteolysis 
 
The Aβ peptide has a spontaneous tendency to oligomerize and it 
can exist in multiple assembly states: monomers, oligomers, protofibrils 
and fibrils (Figure 2). It has been demonstrated in cells derived from 
human brains that Aβ oligomerization begins within the cell rather 
than in the extracellular matrix, but the mechanism of the 
oligomerization remains a mystery (Walsh et al., 2000). The presence of 
multiple Aβ assembly forms highlights the difficulty in attributing 
toxicity to one single Aβ state (Shankar et al., 2009). Recently, it has 
been argued that it is soluble oligomers that evoke neurotoxicity (Haass 
and Selkoe, 2007).  However, it is possible that the toxicity of Aβ is 
mediated by its multiple different assembly states (Hoshi et al., 2003; 
Walsh et al., 2002).  
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Figure 2. Aβ assembly states 
 
2.1.3 Elimination of Aβ 
In normal healthy individuals, Aβ is rapidly eliminated from brain 
(Pluta et al., 1999). There are several different mechanisms and 
pathways to eliminate Aβ from the brain, as Aβ has been reported to be 
degraded by multiple enzymes such as neprilysin and insulin-
degrading enzyme (IDE), and by microglia and astroglia (Evin and 
Weidemann, 2002; Iwata et al., 2002; Wyss-Coray et al., 2003). In brain 
microglia are resident cells of the phagocyte system and they can 
slowly degrade limited amounts of Aβ. Similar to microglia, astroglia 
seem to have some phagocytic capabilities under certain conditions 
(Akiyama et al., 1996; Funato et al., 1998; Thal et al., 1997; Yamaguchi et 
al., 1998). It has been suggested that astrocytes take up Aβ and degrade 
it within their lysosomes (Funato et al., 1998). It seems that the 
phagocytic cells can internalize exogenous Aβ and clear it from brain 
into blood or cerebrospinal fluid. The most significant route of 
elimination of Aβ in young animals and probably in young humans is 
its clearance across the blood-brain barrier by vascular transport  which 
Aβ 
mono
mer 
Oligomers Protofibrils Fibrils 
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is mediated by low-density lipoprotein receptor related protein and α2 -
macroglobulin (Shibata et al., 2000). All of these above-mentioned 
mechanisms appear to fail with age, at least in animals, and possibly 
also in humans (Weller et al., 2004). In older animals and probably also 
in humans, Aβ is mainly eliminated from the brain via the perivascular 
interstitial fluid drainage pathways (Weller and Nicoll, 2003).  Aβ 
appears to enter the perivascular drainage pathway mainly at the level 
of capillaries and drain along perivascular spaces around arteries and 
passes out of the walls of arteries (Preston et al., 2003). The levels of Aβ 
in the walls of leptomeningeal arteries, middle cerebral arteries and the 
basilar artery are greatly increased in the elderly population and 
individuals with AD, but no Aβ is detected in the walls of the 
extracranial arteries (Weller et al., 1998).  At least in AD brains Aβ 
accumulates around arteries five times more commonly than around 
veins (Weller et al., 1998). To summarize, insufficient elimination of Aβ 
from the brain results in its accumulation over time. 
 
2.1.4 Accumulation of Aβ  
The accumulation of Aβ is related to an imbalance between its 
production and elimination. The extracellular aggregates are of 
neuronal origin and are secreted as soluble peptides. The transgolgi 
network is a major reservoir of peptides from which the secreted Aβ is 
packaged into secretory vesicles and transported to the extracellular 
compartment (Greenfield et al., 1999). The extracellular Aβ deposits can 
be classified as fleecy, diffuse or, compact aggregates (Alafuzoff et al., 
2008). Diffuse aggregates are usually large, amorphously shaped and 
their immunoreactivity is weak. They are believed to be the precursor 
for compact aggregates. The compact aggregates are typically 
surrounded by dystrophic neuritis (Duyckaerts et al., 2009; Ingelsson et 
al., 2004). The extracellular Aβ deposits are associated with several 
proteins, lipids and cells such as apolipoprotein E (APOE) and J, zinc, 
copper, iron and various components of the extracellular matrix 
(Duyckaerts et al., 2009).  
In 2002, Thal and colleagues demonstrated the distinct phases of 
parenchymal Aβ deposition in the human brain (Thal et al., 2002). The 
Aβ deposition seems to progress in a sequential pattern and the 
evolution can be classified into 5 different phases (Thal et al., 2002). Aβ 
deposition spreads out anterogradely into regions that receive neuronal 
projections from regions already displaying Aβ.  In the first phase, Aβ 
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deposits are found in the neocortex. In the second phase, Aβ spreads 
out of the allocortical brain regions. In phase 3, Aβ is also found in 
diencephalic nuclei, the striatum and the cholinergic nuclei of the basal 
forebrain. In phase 4, Aβ deposits expand into several brainstem nuclei 
and in phase 5, the cerebellum is involved.  It is noteworthy that the 
distribution of Aβ deposition does not always follow the above phases. 
It has been demonstrated that at least in presenilin-1 mutation carriers, 
Aβ deposition seems to begin in the striatum (Klunk et al., 2007).  
In addition to extracellular Aβ deposits, in 1989, Grunke-Iqbal and 
co-workers reported the presence of intracellular Aβ for the first time 
(Grundke-Iqbal et al., 1989). Since this initial report there have been 
several publications reporting the presence of intracellular Aβ  not only 
in cell culture, but also in the brains of wild and transgenic animals and 
the brains from subjects with Down’s syndrome, AD, human 
immunodeficiency virus, young drug abusers as well as in children and 
aged individuals without any known neurological disorder (Achim et 
al., 2009; Akiyama et al., 1999; Cataldo et al., 2004; Cruz et al., 2006; 
D'Andrea et al., 2001; 2002a; 2002b; 2003; Gomez-Ramos and Asuncion 
Moran, 2007; Gouras et al., 2000; Green et al., 2005; Grundke-Iqbal et al., 
1989; Gyure et al., 2001; LaFerla et al., 1997; Mochizuki et al., 2000; Mori 
et al., 2002; Nagele et al., 2002; Oakley et al., 2006; Ohyagi et al., 2007; 
Ramage et al., 2005; Sheng et al., 2003; Wang et al., 2002; Wegiel et al., 
2007). Mainly because of technical reasons, it has been difficult to 
provide evidence for the presence of intracellular Aβ within neurons. 
The main problem has been the extent of antibody cross-reactivity, as 
Aβ antibodies may also recognize full-length APP or its fragments. 
However, antibodies against neoepitopes have made it possible to 
distinguish Aβ from APP.  In 2000, Mochizuki and colleagues 
demonstrated the presence of Aβ42 immunoreactivity in non-
pyramidal neurons and in 2001 it was noted that Aβ42 could also 
accumulate in the perikaryon of pyramidal cells (D'Andrea et al., 2001; 
Mochizuki et al., 2000). There is also evidence that Aβ42 can be found 
in multivesicular bodies of neurons in the human brain by applying 
immunogold electron microscopy (Takahashi et al., 2002). Today it has 
been accepted that Aβ may accumulate intracellularly but it still 
remains to be confirmed whether the Aβ accumulates intracellularly 
because the produced Aβ is not secreted, or alternatively, whether the 
previously secreted Aβ is internalized from the extracellular pool of Aβ 
(for review Wirths et al., 2004).   
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In addition to intra- and extracellular accumulation of Aβ, Aβ 
accumulates also in the walls of capillaries and arteries within the brain 
and in the walls of the leptomeningeal arteries in the subarachnoid 
space. The accumulation of Aβ in the walls of small and medium sized 
arteries including arterioles and less often veins is a characteristic for 
cerebral amyloid angiopathy (CAA) (Vinters, 1987). The most common 
type of CAA is the sporadic form that frequently co-occurs with AD 
and appears to increase with age. This form of CAA is characterized by 
the accumulation of Aβ in the media and adventitia of parenchymal 
and leptomeningeal vessels (Glenner and Wong, 1984b). Other forms of 
CAA include the heritable CAA types and CAA due to transthyretin 
variants or prion disease (Revesz et al., 2003).  
 
2.1.5 Genetics and Aβ 
Mutations in three genes have so far been clearly associated with 
increased production of Aβ (for review Brouwers et al., 2008). APP 
located on chromosome 21 was the first gene identified in autosomal 
dominant early-onset AD families leading to massive overproduction 
of Aβ (Goate et al., 1991). In Down syndrome, there are three copies of 
this chromosome and this leads the accumulation of Aβ early in the life 
of Down syndrome patients (Gyure et al., 2001; Mori et al., 2002). Since 
the original report in 1991, at least 21 different missense mutations have 
been identified in APP (Brouwers et al., 2008). The mutations in APP 
have an influence on production and the alterations in Aβ sequence 
and Aβ properties lead to an increased aggregation propensity of Aβ 
and increased production of Aβ42 compared to Aβ40 (Brouwers et al., 
2008). In addition to mutations in APP mutations in presenilins PS1 and 
PS2 on chromosomes 1 and 14 increase levels of Aβ42 (Jankowsky et al., 
2004). Mutations in these three genes are known to cause autosomal 
dominant AD (St George-Hyslop and Petit, 2005). There are also several 
other mutations in additional genes that are suspected to have an 
influence on the accumulation of Aβ such as angiotensin converting 
enzyme, prion protein and sortilin-related receptor (Bertram and Tanzi, 
2008).  
 
2.1.6 The role and function of Aβ 
The role and function of Aβ is still an unresolved issue, although it has 
been the focus of intensive investigation for decades. There are at least 
three different hypothesis of the role of Aβ. In 1992, Haass and co-
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workers used cultured cells and demonstrated that Aβ is generated 
continuously as a soluble peptide during normal cellular metabolism. 
In 2003, Kamenetz and colleagues examined hippocampal slice neurons 
and observed that neuronal activity could modulate the formation and 
release of Aβ and they concluded that Aβ may play a role in normal 
synaptic physiology. The hypothesis that Aβ has a role in normal 
cellular mechanism was further supported by Cirrito and colleagues in 
2005. They demonstrated that neuronal release of Aβ was 
physiologically regulated by synaptic activity throughout life by using 
microdialysis probes to measure Aβ levels in brain interstitial fluid and 
simultaneously recording local brain activity in freely moving mice 
(Cirrito et al., 2005).  In 2005 Buckner and co-workers examined 764 
participants using amyloid imaging and they found that the spatial 
pattern of amyloid deposition in elderly individuals with AD correlated 
remarkably well with brain areas of high default brain activity 
(posterior cortical regions including posterior cinculate, retrospenial, 
lateral parietal cortex, and frontal regions along the midline) in young 
adults, supporting the hypothesis that Aβ has also a physiological 
function (Buckner et al., 2005). Interestingly, in these same regions 
myelination seems to happen during late stage of brain development 
(Marsh et al., 2008).  Furthermore, it has been demonstrated by 
examining post-mortem human brain tissue with 
immunohistochemistry that intraneuronal Aβ immunoreactivity 
appears in the first year of life, increases in childhood, stabilizes in the 
second decade of life, and remains high throughout adulthood 
suggesting that the presence of intraneuronal Aβ reflects normal cell 
metabolism rather than a pathological change (Wegiel et al., 2007). 
Taken together the findings from the cell culture, animal and post-
mortem human studies, suggest that neuronal activity modulates local 
Aβ production or secretion or both and that it is possible that Aβ plays 
a role in normal physiology (Cirrito et al., 2005; Haass et al., 1992; 
Kamenetz et al., 2003; Wegiel et al., 2007). 
Another hypothesis is that Aβ is an acute phase protein produced in 
stress situations. This hypothesis is supported by studies focusing on 
traumatic brain injuries. Traumatic brain injury has been shown to 
result in the rapid and long-term accumulation of several key proteins 
including APP and Aβ (Smith et al., 2003). An up-regulation in APP 
gene expression leads to the accumulation of APP in axons and this 
further leads to the increased generation of Aβ (Smith et al., 2003).  
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However, it has also been demonstrated that stress-induced Aβ 
deposits are later degraded and no permanent accumulation of Aβ is 
seen (Nihashi et al., 2001). 
The third hypothesis is that Aβ is a pathological protein. In this 
hypothesis the aggregation of Aβ is believed to trigger a series of steps 
that leads to dementia. The strongest evidence for Aβ being a cause of 
dementia comes from genetics. Missense mutations in the APP or PS1 
or 2 genes have been shown to lead to a massive overproduction of Aβ 
resulting in the accumulation of Aβ in the parenchyma as plaques 
(Goate et al., 1991; Jankowsky et al., 2004). Extracellular Aβ deposition 
has been claimed to lead to synapse and neuron dysfunction and loss of 
neurons, subsequently to atrophy of distinct brain areas and finally to 
dementia (Hardy and Allsop, 1991). However, this hypothesis is 
controversial, as a substantial proportion of elderly population display 
extracellular Aβ deposition without expenencing any neurological 
symptoms and further the extracellular Aβ load does not correlate with 
the severity of cognitive impairment (Bancher et al., 1996, Bennet et al., 
2006; Bierer et al., 1995, Giannakopoulus et al., 2003; Jellinger, 2006b; 
MRC CFAS, 2001). Thus, today the emphasis has switched to the 
soluble Aβ. The term soluble Aβ refers to all forms of Aβ that remain in 
aqueous solution following high-speed centrifugation of physiological 
buffer extracts of brain (Lue et al., 1999; McLean et al., 1999; Wang et al., 
1999). A more robust correlation has been reported between the levels 
of soluble, and not the insoluble Aβ form, and the extent of synaptic 
loss and severity of cognitive impairment (Lue et al., 1999; McLean et 
al., 1999; Wang et al., 1999). In cultured cells, it has been demonstrated 
that soluble, pre-fibrillar aggregates of Aβ may evoke toxicity (Lambert 
et al., 1998). Moreover, in 2002 Walsh and colleagues demonstrated that 
soluble Aβ oligomers and monomers inhibited hippocampal long-term 
potentiation in rats in vivo corroborating the toxicity of soluble Aβ 
(Walsh et al., 2002).  In human post-mortem brain tissue, it has been 
shown that the mean level of soluble Aβ is increased threefold in AD 
cases compared to controls, suggesting that soluble Aβ best explains 
the neurotoxicity of Aβ (Lue et al., 1999; McLean et al., 1999). Despite 
extensive research, the final cascade leading to neuronal death is not 
fully understood and it still remains unclear what role Aβ plays in 
cellular metabolism. 
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2.1.7 Detection of Aβ 
Initially, Aβ was detected by staining with congo red that is relatively 
unspecific chemical staining method. Later thioflavin-S was used to 
visualize Aβ but thioflavin-S was unable to detect diffuse protein 
aggregates. In the late 80’s, a more specific method, 
immunohistochemistry (IHC), was introduced, which detected even 
diffuse protein aggregates. Since then, IHC has been the most 
commonly used method to monitor the accumulation of Aβ in the brain 
tissue. IHC is based on antibodies (Abs) which recognize a specific 
sequence of amino acids (epitopes). An Ab recognizes usually only a 
small part of a longer peptide (Figure 3). Some of the amino acid 
sequences are shared by Aβ and APP and therefore an Ab directed to 
Aβ may also recognize full-length APP or its other derivatives (Figure 
3.). This Ab cross reactivity mainly causes problems when the presence 
of Aβ is assessed in the intracellular compartments where APP is 
physiologically located. In the 1990’s Abs directed to neoepitopes, i.e. 
Abs which recognize the site of a terminal sequence, made it possible to 
differentiate Aβ from APP (LaFerla et al., 2007).  
The antigen retrieval method, i.e. re-exposing and re-shaping of 
critical epitopes, is significant in determining the staining result 
(Alafuzoff et al., 2008; Beach et al., 2008; Christensen et al., 2009; 
D'Andrea et al., 2003; Ohyagi et al., 2007; Sheng et al., 2003).  Formic 
acid is a widely used antigen retrieval method to enhance the 
immunoreactivity of extracellular Aβ, but the effect of formic acid 
pretreatment on the intracellular Aβ is less clear. There are publications 
stating that heat pretreatment is essential for the staining of 
intracellular Aβ, whereas formic acid pretreatment alone is not 
sufficient to visualize the intracellular Aβ (D'Andrea et al., 2003; 
Ohyagi et al., 2007). Formic acid pretreatment is a widely accepted 
method to enhance the immunoreactivity of extracellular Aβ deposits, 
whereas there is no agreement of the optimal antigen retrieval method 
for visualizing the intracellular accumulation of Aβ.  
Until recently the only reliable method to visualize Aβ aggregates in 
the brain was the histological analysis of tissue samples obtained from 
brain biopsy or at autopsy. At the beginning of 2000s, it became 
possible to assess Aβ aggregates in a living patient with a noninvasive 
method positron emission tomography (PET) using Pittsburgh 
Compound B (PIB) (Klunk et al., 2004). Later it was confirmed by 
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frontal cortical biopsy that PIB PET did reflect brain Aβ deposition 
(Leinonen et al., 2008). 
 
  
 
 
Figure 3. A schematic presentation of the Aβ. The epitope regions 
recognized by the antibodies are marked with black 
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2.2 CONCOMITANT BRAIN PATHOLOGIES 
 
2.2.1 Hyperphosphorylated tau-protein 
Another important protein, in addition to Aβ, seen in 
neurodegenerative diseases is hyperphosphorylated tau (HPτ).  Tau 
proteins are encoded by a single gene on chromosome 17 and 
alternative splicing of the exons generates six different tau isoforms 
ranging from 352 to 441 amino acids in length which can be found in 
human brain (Goedert et al., 1989; Neve et al., 1986). Tau protein is one 
of microtubule associated proteins and its main function is to stabilize 
the microtubules (Ebneth et al., 1998). Under normal conditions, tau is 
constantly being phosphorylated and dephosphorylated and there is a 
physiological equilibrium between these two processes. 
Hyperphosphorylation of tau leads it to dissociate from the 
microtubules and to aggregate which makes it neurotoxic (Fath et al., 
2002). HPτ  is a hallmark lesion of neurodegenerative primary 
tauopathies exemplified by sporadic corticobasal degeneration, 
progressive supranuclear palsy, Pick’s disease and hereditary 
frontotemporal dementia and parkinsonism linked to chromosome 17 
(FTDP-17) (Lee et al., 2001).  Mutations in tau gene cause FTDP-17 
where the disruption of tau function directly leads to 
neurodegeneration in the absence of extracellular Aβ deposition, 
corroborating the toxicity of tau  (Poorkaj et al., 1998; Spillantini et al., 
1998).  
AD is the best-known secondary tauopathy where HPτ coexists with 
extracellular Aβ deposition. It has been proposed that an alteration of 
APP metabolism leading to an increased formation and deposition of 
Aβ is the trigger that induces early pathological phosphorylation of τ-
proteins. Later, this assumption was supported by a finding that 
mutations in APP and presenilins cause familial AD with abundant 
HPτ pathology (Hardy and Selkoe, 2002). It was later demonstrated in 
primary cultures of hippocampus and in neuroblastoma cells that Aβ 
oligomers could promote the phosphorylation of τ-protein (De Felice et 
al., 2008). These findings indicate that HPτ pathology is secondary to 
Aβ pathology. However, there are reports indicating that HPτ 
pathology precedes the Aβ deposits by several decades and therefore 
HPτ pathology does not appear to be secondary but a prologue to Aβ 
deposition (Braak and Braak, 1991; Zhou et al., 2006). It is still unclear 
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how these two proteins affect each other and which one is the initiator 
of pathological cascade leading to neuronal death. 
 
2.2.2 α-Synuclein 
α-Synuclein (αS) is an abundant presynaptic protein that is mainly 
expressed in the brain as an isoform of 140 residues (Goedert, 2001). 
The physiological function of αS is not well established, but it has been 
postulated that αS may have a role in physiological regulation of 
certain enzymes, transporters, and neurotransmitter vesicles, as well as 
in neuronal survival (Dev et al., 2003; Lotharius and Brundin, 2002). αS 
is natively unfolded in a manner similar to tau (Weinreb et al., 1996).  
The most common type of αS-containing inclusion is the Lewy body 
(LB), a rounded eosinophilic inclusion in the cell soma (Spillantini et al., 
1997). LBs and Lewy neurites (LNs) are a common pathological 
hallmark of Parkinson disease but they are also detected in brains with 
other neurodegenerative diseases such as AD and dementia with Lewy 
bodies (DLB) and they are quite commonly detected in the brains of the 
elderly population who do not display any neurological or psychiatric 
symptoms (Jellinger, 2004; Parkkinen et al., 2005). αS pathology seems 
to progress in a sequential pattern and this regional distribution of αS 
immunoreactivity is the basis of neuropathological staging of PD/DLB 
related pathology (Braak et al., 2003; McKeith et al., 1996). It has been 
speculated that during the early stages, αS pathology would be 
confined to the brainstem regions, resulting in a clinical presentation of 
PD and later, the pathology spreads to the allo- and neocortex and the 
clinical presentation at this stage is DLB/Parkinson disease with 
dementia (PDD) (Braak et al., 2003; Perry et al., 1990).  
αS-positive lesions are common in familial and sporadic AD 
patients, estimates ranging from 50-60% and in Down syndrome 
patients (Arai et al., 2001; Hamilton, 2000; Lippa et al., 1999). The 
overlap in the pathological and clinical features suggests that these two 
types of pathologies may be linked (Giasson et al., 2003). In vitro 
models it has been demonstrated that αS can induce the fibrillation of τ-
protein and further αS and τ-protein can promote eact other’s 
polymerization (Giasson et al., 2003; Jensen et al., 1999). Furthermore, 
increased levels of Aβ, at least in the transgenic mouse model, can 
promote the accumulation of fibrillar αS into inclusions and vice versa 
αS has been shown to enhance the aggregation of Aβ in vitro models 
(Jensen et al., 1997; Masliah et al., 2001). Thus, αS, HP τ and Aβ 
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pathology regularly co-exist and it seems that these different proteins 
can affect each other either directly or indirectly. However, their 
functions under normal physiological conditions as well as their role in 
disease still remain to be clarified.  
 
2.3 NEURODEGENERATIVE DISEASE AND NORMAL AGING 
 
2.3.1 Alzheimer’s disease 
AD is the most common progressive neurodegenerative disease 
worldwide resulting in severe cognitive impairment and leading to 
death within about 10-15 years. AD is the leading cause of late-life 
dementia accounting for approximately 54 % of all dementias (Lobo et 
al., 2000). The lifetime risk for AD is 33% for men and 45% for women 
between the age 65 and 100 years. The prevalence of AD increases 
strongly with age. It is approximately 1,5 % in the seventh decade and 
increases to as high as 50 % in the tenth decade (van der Flier and 
Scheltens, 2005). Typical clinical symptoms are memory problems, 
executive dysfunction, visuospatials difficulties, aphasia, apraxia and 
agnosia.  
Neuropathology is proposed to be the golden standard for 
diagnosing AD. Aβ deposition in the form of diffuse and neuritic 
plaques (NPs) and accumulation of HPτ in the form of neurofibrillary 
tangles (NFTs) in neuronal cell bodies and neuropil threads (NTs) in 
neuronal processes are the classic neuropathological features of AD 
(Bancher et al., 1989; Braak et al., 1986; 1994; Braak and Braak, 1997; 
Grundke-Iqbal et al., 1986). The first consensus guidelines for the 
assessment of AD-related hallmark lesions, NPs, NFTs and NTs, were 
published in 1985 (Khachaturian, 1985). The neuropathological 
diagnosis of AD was based on the quantitative assessment of both NPs 
and NFTs in relation to the patient’s age and the clinical history. 
However, this quantification proved to be overtly complicated, and 
thus in 1991 revised guidelines were launched known as CERAD 
strategy which provided details on the likelihood of AD (Mirra et al., 
1991).  The CERAD strategy did not pay any attention to the regional 
distribution of HPτ and Aβ. In the same year, the Braak staging was 
introduced which was based on hierarchical and topographical 
distribution of HPτ pathology (Braak and Braak, 1991). At that time, the 
Braak staging system was based on an assessment of two 100 µm thick 
sections processed according to the silver technique proposed by 
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Gallyas (Braak and Braak, 1991; Gallyas, 1971; Gallyas, 1979; Iqbal et al., 
1991).  In 2006, this staging strategy was modified to incorporate the 
use of HPτ IHC and 5-15µm thick paraffin embedded sections (Braak et 
al., 2006). In the Braak staging system, the trans-entorhinal and 
entorhinal cortex (stages I-II), then the hippocampus (stages III-IV) and 
finally the isocortex (stages V-VI) are sequentially involved (Braak and 
Braak, 1991). When the lesions reach the isocortex, overt clinical 
symptoms of dementia can be observed. The Braak staging procedure is 
still commonly used in routine neuropathology. The currently used 
consensus recommendations for post-mortem diagnosis of AD were 
launched in 1997 by the National Institute on Aging and Reagan 
Institute (NIA-RI) working group. These recommendations are based 
on Braak staging for HPτ pathology and CERAD classification for NPs 
(infrequent, moderate and frequent) resulting in a statement of 
likelihood that dementia is caused by AD.   
The pathogenesis of AD is still unclear. The amyloid cascade 
hypothesis has been the dominant theory for more than a decade. It has 
been postulated that the generation of Aβ initiates a pathological 
cascade leading to dementia (Hardy and Allsop, 1991). The cascade 
begins when some unknown factor increases the formation of Aβ or 
decreases its clearance from the brain. Aβ oligomerization and 
accumulation occur first and the accumulation of HPτ pathology and 
neuronal dysfunction are secondary events. The strongest evidence for 
this hypothesis comes from genetics. The mutations in APP and 
enzymes that mediate the cleavage of Aβ (PS1 and 2) lead to massive 
overproduction of Aβ and early onset of AD. However, PS1 mutations 
can also lead to tauopathy without the presence of Aβ deposition (Baki 
et al., 2004; Dermaut et al., 2004). Patients carrying the tau mutation 
display severe NFT pathology and cognitive impairment without 
exhibiting Aβ indicating that HPτ is neurotoxic. The strongest evidence 
against the amyloid cascade theory comes from clinicopathological 
studies, as no correlation between the extracellular Aβ load and the 
severity of cognitive decline has been found (Bierer et al., 1995; 
Giannakopoulos et al., 2003). In contrast, a strong correlation between 
the HPτ pathology and the severity of cognitive impairment has been 
observed in many studies (Bancher et al., 1996; Berg et al., 1998; Bierer 
et al., 1995; Giannakopoulos et al., 2003; Gold et al., 2001).  Furthermore, 
the removal of extracellular Aβ plaques did not prevent the progression 
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of AD challenging the role of Aβ in the pathogenesis of AD (Holmes et 
al., 2008). 
Several studies have described alterations in the immune system in 
AD. These studies have implied that the immune system is capable of 
recognizing as abnormal the proteins that accumulate in brain in AD 
(for review Boche and Nicoll, 2008). Inflammation in AD has been 
considered to contribute to disease progression specifically in the form 
of microglia activation (Boche and Nicoll, 2008; Duyckaerts et al., 2009). 
An association between activated microglia and the counts of NFTs has 
been reported but not between activated microglia and the load of NPs 
(DiPatre and Gelman, 1997; Overmyer et al., 1999b). However, this 
association is modified by APOE ε4 allele, as the correlation has been 
reported to be significant only in those subjects without the ε4 allele 
(Overmyer et al., 1999b). Currently, the exact role of microglia is 
unknown and whether they are harmful or helpful in pathogenesis of 
AD is still unclear. In contrast to microglia, an increase in the load of 
reactive astrocytes has been reported to co-occur in parallel with an 
increase in load of the extracellular Aβ, suggesting that Aβ deposition 
may stimulate astroglia to become reactive (Overmyer et al., 1999a; Pike 
et al., 1994). It has also been proposed that Aβ deposition can induce 
cytokine expression in astrocytes but the role of cytokines in the 
pathogenesis of AD remains unclear (Gitter et al., 1995; Hu et al., 1998). 
As well as the microglia and astroglia, the complement system is 
activated in AD (Rogers et al., 1992) and it has been suggested that the 
complement system may have a protective role in AD (Boche and 
Nicoll, 2008). Furthermore, a decrease of anti-Aβ antibodies in AD 
patients compared with healthy controls suggests that some individuals 
are able to immunize themselves against Aβ. In summary, in AD 
alterations in the immune system are seen, but it is still unclear whether 
this is beneficial or harmful. The molecular cascade leading to 
neurodegeneration and neuronal death in AD is not fully understood 
which prevents the development of a curative treatment.  
 
2.3.2 Dementia with Lewy Bodies 
Already in the early 1960’s Okazaki and co-workers described two 
patients with widespread LB pathology throughout the cortex and with 
progressive cognitive impairment (Okazaki et al., 1961). In the mid 70’s, 
this finding was confirmed by Kosaka and co-workers indicating that 
diffuse cortical spread of LB pathology could be responsible for 
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cognitive impairment (Kosaka et al., 1976; Kosaka, 1978). After these 
original studies, numerous reports have described widespread LBs in 
the cerebral cortex and brain stem in demented Parkinson patients and 
in patients who were demented with a clinical picture atypical of AD 
associated with mild parkinson features (Dickson et al., 1987; Gibb et 
al., 1987; Perry et al., 1989; Perry et al., 1990). At a consensus conference 
held in 1996, the clinical and neuropathological features of DLB were 
identified (McKeith et al., 1996). The key cognitive features of DLB are 
fluctuating attentional deficit, severe visuoperceptual impairments, and 
relative preservation of episodic memory as compared with AD.  Before 
one can make a neuropathological diagnosis of DLB it is essential to 
observe αS immunopositive LNs and LBs in the cerebral cortex 
(McKeith et al., 1996).  However, LBs are often found in the cerebral 
cortex in elderly individuals who do not exhibit any neurological or 
psychiatric symptoms (Colosimo et al., 2003; Lindboe and Hansen, 
1998; Parkkinen et al., 2005; Yoshinobu et al., 2003) and therefore the 
assumption that the absolute number of cortical LBs alone would be 
responsible for the cognitive impairment is oversimplistic. Recent 
studies have indicated that the presence of Aβ deposition in the 
cerebral cortex was associated with extensive αS load leading to the 
conclusion that Aβ enhances the development of LBs (Jellinger, 2006b; 
Pletnikova et al., 2005). These results may point to some synergistic 
reactions between Aβ and αS but the molecular background to the 
pathogenesis of DLB remains to be elucidated.  
 
2.3.3 Vascular cognitive impairment 
VCI is considered the second most common cause of age-related 
dementia after AD accounting for 15-20% of all dementias worldwide 
(Lobo et al., 2000). The prevalence figures of VCI vary considerably 
depending on which diagnostic criteria are applied (Bowler, 2007; 
Jellinger, 2007). VCI is a heterogenous disorder that refers to all forms 
of mild to severe cognitive impairment presumed to be caused by 
stroke, multiple cortical and/or subcortical infarcts, silent infarcts, 
ischemic lesions in functionally important brain areas, small vessel 
disease with white matter lesions (O'Brien et al., 2003). Multiple small 
infarcts and small vessel disease are more often a substrate of VCI than 
a single major infarct (Bowler, 2007). Lacunar infarcts and multiple 
microinfarcts in the basal ganglia, thalamus, brainstem and white 
matter are often seen in VCI cases consistent with subcortical VCI 
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which is the most common variant of VCI accounting for 40% of VCI 
cases (Bowler, 2007; Erkinjuntti et al., 2000; Erkinjuntti, 2003).  
The relationship between stroke and dementia is complex and 
controversial. There are three pathological types of stroke: ischemic 
stroke accounting for 80% of cases, primary intracerebral hemorrhage 
(about 15%), and subarachnoid hemorrhage (about 5%) (Warlow et al., 
2003). Approximately half of ischemic strokes are due to 
atherothrombotic disease, 20 % are caused by cardioembolus, about 25 
% are due to intracranial small-vessel disease, with the remaining 5% of 
strokes being due to other rare causes (Warlow et al., 2003). Cognitive 
impairment is frequently encountered after ischemic stroke. The 
estimates of the prevalence of cognitive decline after a stroke vary from 
5-30% (Barba et al., 2000; Kokmen et al., 1996; Leys et al., 2005; Rasquin 
et al., 2004; Tatemichi et al., 1990).  It has been estimated that 25-30% of 
patients with stroke meet the criteria for dementia at 3 months after a 
stroke (Barba et al., 2000; Pohjasvaara et al., 1997) and the majority of 
subjects who become demented after stroke will develop the symptoms 
in the first year (Desmond et al., 2000; Pohjasvaara et al., 1998). In a 
longitudinal study, the risk of incident dementia was increased 4-fold 
among stroke patients who were initially cognitively intact when 
compared with clinically stroke-free elderly control subjects (Desmond 
et al., 2002). In a population based study the risk of dementia was 
increased 9-fold in the first year after stroke and the risk for dementia 
each year thereafter in a cohort was about twice the risk of the general 
population (Kokmen et al., 1996).  
Furthermore, white matter lesions are commonly seen in VCI, but 
their contribution to cognitive impairment is not explicit (Kalaria et al., 
2004), because they are frequently observed in magnetic resonance 
imaging scans in both cognitively intact and demented elderly persons 
(Longstreth et al., 1996; Scheltens et al., 1992).  
 
2.3.4 Combined brain pathologies 
The majority of the elderly population exhibits brain pathology and 
those with dementia most often have multiple brain pathologies 
(Schneider et al., 2007). Schneider and co-workers evaluated 141 well-
characterized community-dwelling older individuals and they found 
that those subjects with more than one neuropathological diagnosis 
(AD, DLB, infarcts) have an almost threefold increase in their odds of 
developing dementia compared to those with a single pathology  
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(Schneider et al., 2007). Already, in 1970 Tomlinson and co-workers 
reported that most demented males exhibited the pathological features 
of AD and arteriosclerotic dementia when they examined the brains 
from 50 demented subjects (Tomlinson et al., 1970). One year later Roth 
and colleagues reported that the two types of pathological change 
increase the risk of dementia (Roth et al., 1971). In the elderly 
population most commonly infarcts and AD co-exist (Kalaria, 2000). In 
patients with CVD who also have AD type pathology have a worse 
cognitive outcome and it is also known that the interaction between 
these two components more than doubles the risk of cognitive 
impairment (Snowdon et al., 1997; Tyas et al., 2007). However, the 
association between CVD and AD is complex. Epidemiological studies 
suggest that there are overlaps and some synergistic effects between 
AD and CVD pathology, but the results of these studies have been 
controversial.  Jellinger and Attems examined 730 AD patients and 535 
age-matched controls and they found that the prevalence of CVD 
pathology in AD cases was significantly higher than in controls 
(Jellinger and Attems, 2003). CVD seems to lower the threshold of AD 
pathology required for the clinical expression of dementia (Esiri et al., 
1999; Mungas et al., 2001; Snowdon et al., 1997). However, the 
underlying interaction between CVD and AD is still unknown (Jellinger 
and Attems, 2005).  It has been proposed by Jendroska and colleagues 
that ischemic episodes may lead to stress-induced production of Aβ 
and favour the accumulation of Aβ in the gray matter of cerebral artery 
boundary zones and in this way cerebral ischemia may contribute to 
the pathogenesis of AD (Jendroska et al., 1995).  Similar results were 
recorded in the study of Nihashi and co-workers. They found that Aβ 
was up-regulated in reactive astrocytes after ischemic stress, but this 
did not result in permanent Aβ deposition (Nihashi et al., 2001). It has 
also been proposed that CVD may inhibit the elimination of Aβ along 
arteria walls and change the distribution of Aβ in the cerebral cortex 
(Weller et al., 2002). However, in human post-mortem studies, no 
association between the presence of CVL and the load of Aβ deposits or 
NFTs has been found (Honig et al., 2005; Mastaglia et al., 2003).  In 
theory, small vessel disease may impair the elimination of Aβ along 
perivascular route and consequently lead to the accumulation of Aβ. 
However, there are no human post-mortem studies where an 
association between small vessel disease and the load of Aβ deposits 
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and NFTs would have been detected. Today, the interaction of CVD 
and AD remains to be clarified.  
In the study of Jellinger, 1050 elderly demented individuals were 
studied. Among those individuals only 45 % displayed a pure form of 
AD, 23 % displayed additional CVL and 11% exhibited also LB 
pathology indicating that most demented elderly subjects display 
multiple pathologies (Jellinger, 2006b).  In conclusion, all additional 
pathologies that frequently occur in the aged brain seem to lower the 
threshold for the appearance of the pathology required for the clinical 
expression of dementia (Snowdon, 1997; Snowdon and Nun, 2003).  
 
2.3.5 Aging and brain pathology 
A wide variety of morphological and functional alterations are common 
in the brain of aged individuals. It has long been known that a 
substantial proportion of the elderly population displays 
neuropathological changes of AD such as NFTs, NTs and NPs 
(Tomlinson et al., 1968).  In community based studies, the prevalence of 
neocortical HPτ pathology, i.e. Braak stage V-VI, has varied between 4-
34% of cognitively intact subjects (Bennett et al., 2006; McKee et al., 
2006; MRC CFAS, 2001). Some NFTs are present in the enterorhinal 
cortex and hippocampus of most elderly individuals irrespective of 
their cognitive status (Haroutunian et al., 1999).  These results provide 
evidence that some type of neural reserve, or some other defense or 
adaptive mechanism can allow a sizeable percent of aged individuals to 
tolerate a significant amount of AD pathology without the appearance 
of the clinical symptoms of dementia (Bennett et al., 2006; Snowdon and 
Nun, 2003).  In the Nun Study, a longitudinal study of aging, as many 
as 8% of participants who, on autopsy displayed severe AD pathology 
(Braak stage V-VI) while alive, did not show any signs of dementia and 
stroke-free participants seemed to tolerate even more AD pathology in 
their brain before manifesting dementia than subjects with CVL 
(Snowdon et al., 1997). Therefore the absence of other co-morbid 
conditions may help an individual to resist the clinical appearance of 
symptoms that could be expected in view of the existing 
neuropathology (Snowdon, 1997; Snowdon and Nun, 2003). Likewise 
AD related pathology αS can be detected in the neocortex in elderly 
subjects who do not display any neurological or psychiatric symptoms 
(Jellinger, 2004; Parkkinen et al., 2005).  The concept of successful 
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ageing has provoked considerable interest, but little is known about the 
neuropathology of healthy aging (Tyas et al., 2007). 
 
2.4 FACTORS INFLUENCING ON THE ACCUMULATION OF Aβ 
 
2.4.1 Apolipoprotein E 
The only well-established gene associated with an increased risk of late 
onset AD is APOE ε4 allele. APOE is a plasma protein mainly produced 
by astrocytes in the brain. It regulates lipid transport and metabolism 
and neuronal repair in the central nervous system but it also has other 
functions including immunoregulation and modulation of cell growth 
and differentiation (Dik et al., 2001; Duyckaerts et al., 2009; Mahley, 
1988). APOE has a role in the regenerative response of injured nerves 
but it is also associated with neurodegenerative diseases (Strittmatter et 
al., 1993). APOE is encoded by the APOE gene on chromosome 19 (Emi 
et al., 1988). There are three different alleles for APOE: ε2, ε3, and ε4 
and these three different alleles give rise to three different APOE 
isoforms which means that there are six possible genotypes (Emi et al., 
1988; Mahley, 1988).  A well-known risk factor for late-onset AD is the 
APOE ε4 allele (Corder et al., 1993; Martinoli et al., 1995; Saunders et 
al., 1993). The presence of the APOE ε4 allele is associated with 
increased total cholesterol levels leading to an increase in the risk of 
atherosclerosis (Davignon et al., 1988; Slooter et al., 1999). Therefore, it 
could be predected that APOE would be associated with AD through 
atherosclerosis. However, atherosclerosis has not proved to be an 
intermediate factor and it does not explain the association between 
APOE and AD (Alafuzoff et al., 1999; Slooter et al., 1999). APOE ε4 
allele has been proposed to promote the formation of Aβ by regulating 
proteolytic degradation of Aβ or to affect the clearance of Aβ, since an 
increased number of NPs has been found in the cerebral cortex of 
APOE ε4 homozygotes (Alafuzoff et al., 1999; Mahley et al., 2006; 
Schmechel et al., 1993; Tiraboschi et al., 2004).  In PS1 mutation carriers 
the load of Aβ is also higher in subjects with the APOE allele ε4 than 
with the other alleles (Martikainen et al., 2010).  
The role of APOE ε2 allele in AD is controversial. In 1995 van Duijn 
and colleagues reported that ε2 allele is a risk factor for early onset AD 
(van Duijn et al., 1995). This finding was contradicted in 1997 when 
Farrer and co-workers concluded that the ε2 allele could protect from 
AD (Farrer et al., 1997). In other studies no relationship between ε2 
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allele and the risk of AD has been found (Frikke-Schmidt et al., 2001; 
Scott et al., 1997; Yip et al., 2002). The biological mechanism by which 
different APOE isoforms are related to the pathogenesis of AD is still 
under debate, even though there is agreement that APOE ε4 is a strong 
risk factor for sporadic AD.  
 
2.4.2 Atherosclerosis 
The deposits of cholesterol in the walls of arteries are the culprits in 
atherosclerosis. In an epidemiological study, an association between 
atherosclerosis and AD has been revealed (Hofman et al., 1997). Studies 
investigating the association between atherosclerosis and the hallmark 
lesions of AD such as Aβ deposits and NFTs have reported conflicting 
results. In 2005, Honig and colleagues analyzed 921 subjects with a 
neuropathologic diagnosis of AD and 133 subjects considered as 
neuropathologically normal (Honig et al., 2005). They found that 
atherosclerosis was associated with an increased frequency of Aβ 
deposits, though other neuropathological studies have not corroborated 
this finding (Alafuzoff et al., 1999; Luoto et al., 2009).  
It has been postulated that an atherosclerotic occlusion of the circle 
of Willis and leptomeningeal arteries plays an important role in the 
pathogenesis of AD (Kalback et al., 2004) and further, in cross-sectional 
studies, the extent of high-grade carotid stenosis has been found to 
correlate with cognitive impairment (Johnston et al., 2004; Mathiesen et 
al., 2004)  The stenosis may result in a decrease in perfusion pressure, 
and these hemodynamic disturbances have been suggested to 
contribute to sporadic AD (Kalback et al., 2004). Hypoperfusion has 
also been considered as the main etiology of white matter lesions that 
have been suggested predicting dementia (Pantoni and Garcia, 1997; 
Prins et al., 2004). To summarize, it seems do not accelerate the 
formation of NFTs or Aβ deposits.  
 
2.4.3 Diabetes 
Diabetes mellitus (DM) is a group of metabolic diseases characterized 
by hyperglycemia. Chronic hyperglycemia is associated with long-term 
damage of several organs. DM is caused by an inherited or acquired 
defect in insulin production by the pancreas, or by the ineffectiveness of 
the released insulin to exert its physiological effects (insulin resistance). 
Type I DM results from autoimmune destruction of the β-cells of the 
pancreas leading to absolute insulin deficiency, whereas type II DM 
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predominantly results from insulin resistance with relative insulin 
deficiency (American Diabetes Association, 2005). The prevalence of 
DM is increasing with this increase mainly attributed to an increase in 
the numbers of patient with type II DM that is strongly associated with 
lifestyle changes, obesity, inactivity and urbanization (American 
Diabetes Association, 2005).  
DM is a well established risk factor for stroke and it associates with 
small and large vessel diseases such as white matter lesions and 
infarctions (Arvanitakis et al., 2006). Thus, it is consistent that DM has 
been shown to increase the risk of VCI (Xu et al., 2004). A causative 
association between DM and AD has been proposed based on clinical 
and epidemiological studies, but the results have been controversial. 
According to population based studies, the risk of AD in diabetics is 
elevated (Leibson et al., 1997; Ott et al., 1999). In contrast large clinical 
studies have not been able to corroborate these findings (Akomolafe et 
al., 2006; MacKnight et al., 2002; Xu et al., 2004). Regardless of 
numerous epidemiological and clinical studies where a connection 
between AD and DM has been claimed, there are few studies where 
this relationship has been explored at the molecular level. If DM 
elevates the risk of AD, it could be anticipated that an association 
between AD related pathology such as HPτ and Aβ could be found. 
However, in post-mortem studies no association between DM and AD 
related neuropathological changes has been detected (Arvanitakis et al., 
2006; Heitner and Dickson, 1997).  
In 2004, Luchsinger and colleagues reported an association between 
a higher risk of AD and hyperinsulinemia (Luchsinger et al., 2004). 
Hyperinsulinemia precedes hyperglycemia by many years before the 
onset of type II DM and after the onset of disease, many of patients still 
exhibit hyperinsulinemia (Laakso, 1993; Weyer et al., 2000). The link 
between hyperinsulinemia and AD is the insulin-degrading enzyme 
(IDE) which degrades insulin, pancreatic amylin as well as extracellular 
Aβ (Qiu and Folstein, 2006). In the brain IDE is involved in eliminating 
of extracellular Aβ. IDE is inhibited by insulin and it has been 
suggested that this inhibition results in an increase in the levels of Aβ 
and leads to increased AD pathology (Luchsinger et al., 2004; Qiu and 
Folstein, 2006). Furthermore, it has been proposed that insulin can 
stimulate the phosphorylation of τ-protein and hence, 
hyperinsulinemia may increase the formation of NFTs and decrease the 
elimination of Aβ, resulting in a total increase in AD pathology 
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(Gasparini et al., 2002). However, there is no consenus in the findings 
from post-mortem studies to confirm this hypothesis, and thus the 
association of DM and AD still needs to be clarified.  
 
2.4.4 Alcohol abuse 
Epidemiological and case-control studies have shown that excessive 
consumption of alcohol, meaning an alcohol intake of more than 300 
grams of ethanol per week, is a risk factor for stroke and furthermore it 
can lead to an impairment of cognitive function (Hillbom, 1998; 
Letenneur, 2004; Saunders et al., 1991). When specific alcohol related 
disorders, such as Wernicke’s syndrome, hepatic encephalopathy and 
pellagra are excluded; there is still a group of heavy alcohol consumers 
(HAC) exhibiting cognitive impairment (Harper and Scolyer 2004). A 
direct toxic effect of ethanol on brain has been postulated as the 
primary cause of alcohol related dementia (Sun and Sun, 2001) 
However, the specific and discrete pathological mechanism remains a 
mystery and thus, the existence of primary alcohol related dementia is 
still a matter of debate.  
Epidemiological and case-control studies have provided conflicting 
results as to whether alcohol intake plays a role in the risk of AD. 
Several studies have indicated that alcohol consumption has no effect 
on the development of AD (Graves et al., 1990; Huang et al., 2002; 
Rosen et al., 1993; Tanaka et al., 2002) though opposite results have also 
been reported (Fratiglioni et al., 1993). In very few studies has the 
relationship between alcohol consumption and the hallmark lesions of 
AD been evaluated. Already in 1984, Paula-Barbosa and Tavares 
reported that neuritic plaques were observed in rats following chronic 
alcohol consumption but subsequently Freund and Ballinger in 1992 
reported that neuritic plaque counts were not increased in the brains of 
alcoholics compared with non-alcoholics, when they investigated 
human autopsy brains from 20 alcoholics and 20 controls (Paula-
Barbosa and Tavares, 1984; Freund and Ballinger, 1992). Later, Gendron 
and coworkers demonstrated that ethanol could enhance HPτ 
accumulation in neuroblastoma cells and Sun and colleagues showed 
that, in rats, bilateral injection of isoproterenol into hippocampus could 
induce hyperphosphorylation of τ suggesting that alcohol intake could 
accelerate the development of neurofibrillary tangles i.e. the hallmark 
lesions of AD (Gendron et al., 2008; Sun et al., 2005). Thus, there is no 
consensus agreement about the role of alcohol consumption in the 
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development of AD. Despute the many epidemiological studies where 
a connection between dementia and alcohol intake has been claimed, 
there are very few studies where this relationship has been explored at 
the molecular level.  
 
2.5 ANIMALS AS MODELS FOR NEURODEGENERATIVE DISEASES  
 
Animal models have played a major role in helping to understand the 
mechanisms of neurodegenerative diseases and in developing potential 
therapeutic approaches. However, due to the differences between 
animals and humans, results obtained from animal studies as such 
cannot be directly generalized to humans (Harding et al., 1997). It has 
been shown in vivo that transcription factors responsible for gene 
expression diverge between humans and mice (Odom et al., 2007).  
Similar to the situation with the transcription factors, it can be assumed 
that epigenetic factors, DNA methylation and histone modifications, 
also diverge between species. In addition to these physiological species 
differences, in AD research most findings emerge from animal models 
that overproduce Aβ based on mutations seen in familial AD, and thus 
they do not provide information about the more common sporadic AD. 
Moreover, transgenic mice models based on APP mutations, that are 
known to influence the production and aggregation of Aβ42, exhibit Aβ 
peptides which are in a higher aggregation state when compared to 
humans (Christensen et al., 2009). Due to these species differences, the 
results obtained from animal models invariably need to be re-evaluated 
in human studies. 
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3 Aims of the study 
 
The extracellular accumulation of Aβ is linked to several 
neurodegenerative diseases and it is thought to be a key factor in the 
pathogenesis of AD. However, Aβ deposits are commonly seen in the 
brains of the elderly population who do not seem to suffer from any 
neurological disorders, challenging the role of Aβ as an initiator of the 
pathological cascade. Epidemiological and animal studies have 
postulated that there is a connection between the accumulation of 
extracellular Aβ and different risk factors such as CVL, DM, alcohol 
abuse and synucleinopathy indicating that ischemic stress, metabolic 
disturbances, toxic stress, or concomitant pathology would elevate the 
load of Aβ, and accelerate the neurodegenerative process. The objective 
of this study was to assess these proposed associations in a large 
human post-mortem cohort.  
 
The specific aims were: 
 
1. To assess if CVL would have any influence on the 
 accumulation of extracellular Aβ in the cortex and thalamus 
 (study I).   
 
2. To estimate the prevalence of Aβ and HPτ pathology in 
 subjects who display αS pathology, and to investigate the 
 relationship between different pathological processes as 
 underlying subsrates for cognitive impairment, and further 
 to assess the clinical relevance of Aβ deposits in the  striatum 
 (study II). 
 
3. To test the proposed hypothesis that DM can influence the 
accumulation of Aβ (study III). 
 
4. To evaluate the proposed association between alcohol abuse and 
the neuropathological hallmark lesions of AD, DLB and VCI 
(study IV).  
 
5. To test the reliability of the immunohistochemistry technique 
while assessing intracellular Aβ in routine diagnostic human 
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post-mortem material, and to investigate the influence of 
antibody choice and antigen retrieval method on the obtained 
staining result (study V). 
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4 Subjects and methods 
 
4.1 CASE SELECTION 
 
The study cohort included individuals who underwent an autopsy 
including a neuropathological examination in the Department of 
Pathology of the Kuopio University Hospital that serves a catchment 
area of approximately 250 000 people.  The mortality rate is around 10 
%, given an annual rate of death at 2500 individuals. The autopsy rate is 
estimated to be 32 % and hence approximately 800 individuals undergo 
a medical or forensic autopsy in any year in the Kuopio University 
Hospital. The study cohort was collected during the years 1991-2005, 
but only from 1996 were the brain samples systematically taken from 
different brain regions. During a 10-year period (1996-2005), 1720 
individuals underwent an autopsy including an examination of the 
brain and therefore the study cohort represents approximately 8 % of 
all deaths over 10 years in the catchment area of the Kuopio University 
Hospital.  
Figure 4 describes the scheme involved in the selection of the 
material in studies I-III.  In study IV, all individuals were included who 
were subjected to a forensic autopsy including a neuropathological 
examination during a six month long period in 1999. Following the 
legislative protocols, a forensic autopsy is carried out on all subjects 
dying at home when there is a lack of sufficient medical history which 
would permit assessment of the cause of death, on all subjects who had 
died in accidents, as victims of homicide or suicide or who were 
suspected to be victims of malpractice.  
Study V was performed on surgical biopsy material and post-
mortem human brain tissue. The surgical sample had been obtained 
from a patient who had undergone intracranial pressure monitoring 
with frontal cortical biopsy for suspected normal pressure 
hydrocephalus.  
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Subjects with clinical signs of 
dementia were excluded 
746 subjects with CVL 
The clinical data were collected retrospectively from medical records. 
The study cohort included all subjects, age at death > 40 years, who had 
been autopsied which included a neuropathological examination of the brain 
during the years 1991-2005 in the Kuopio University Hospital. 
 
178 subjects with αS IR 
in the substantia nigra 
or/and in the 
amygdaloid nucleus 
Study I 
1996-
2004 
n=1506 
Study II 
1996-
2005 
n=1720 
Study III 
1991-
2000 
n= 703 
 
484 CVL subjects  
57 age-matched controls 
134 diabetics 
574 non-diabetics 
Immunohistochemical methodology was used to visualize Aβ, HPԏ, and αS. 
98 non-demented 
80 demented 
Figue 4. Study flow chart 
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4.2 CLINICAL ASSESSMENT 
 
The clinical data were collected retrospectively from the medical 
records in studies I and V by LA and for study III by HS.  In study IV, 
the information of alcohol consumption was collected from medical 
records, police reports and from close relatives by JJ. The diagnosis of 
dementia was based on the Diagnostic and Statistical Manual of Mental 
disorders, Revised Third Edition, 1987 (DSM-III-R criteria), the most 
widely used criteria for dementia. However, some of the cases, who 
were classified as non-demented, might have displayed very mild 
cognitive impairment that had not been recognised during their 
lifetime, though it is unlikely that the presence of moderate or full-
blown dementia would have been overlooked.  Nearly all subjects 
included in studies II and III had been under continuous clinical follow-
up due to some chronic disease and most subjects had been examined 
by a neurologist and all had at least visited a general physician. In 
study III, the subjects were considered to have diabetes if a random or 
post-load serum glucose level had been greater than 11 mmol/l and the 
medical records revealed that they had been on medication because of 
diabetes. In study IV, an individual with socially disabling alcohol use, 
daily alcohol use, and continued drinking in spite of the indisputable 
health-related and / or social damage was classified as a heavy alcohol 
consumer (HAC).  
 
4.3 NEUROPATHOLOGICAL ASSESSMENT 
 
Following a standardized dissection protocol, all brains were routinely 
weighed, evaluated for grossly detectable lesions, fixed in 4 % buffered 
formaldehyde for at least 1 week, and cut into coronal slices. Prior to 
slicing, the severity of atherosclerosis of arterial circle of Willis was 
graded on a four step scale from none, mild, moderate to severe. 
Macroscopically detectable lesions were assessed on all fixed coronal 
slices (thickness = 1 cm) and noted as being present or not. For all cases, 
the brain specimens were systematically taken from the following 15 
brain regions: frontal, temporal, parietal, precentral, occipital cortices, 
gyrus cinguli, striatum, basal forebrain including amygdala, thalamus, 
hippocampus, and midbrain including substantia nigra, pons including 
locus ceruleus, medulla, vermis, cerebellar cortex, and additionally 
from any grossly notable lesion. Neocortical sections were routinely 
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taken from the right hemisphere and in a case where grossly detectable 
lesions were seen, additional sections were taken from the non affected 
left hemisphere. In study IV, subjects underwent a medico-legal 
autopsy including an examination of brain.  The brains were weighed, 
evaluated for grossly detectable lesions and cut into 1 to 2 cm-thick 
coronal slices. A central 2 cm thick coronal slice was retrieved and 
placed in formalin to permit a detailed neuropathological assessment. 
The anterior cut was through the mamillary bodies. Two weeks later, 
brain specimens were taken from 7 neuroanatomical regions including 
temporal cortex, cingulated gyrus, parietal cortex, striatum, basal 
forebrain including amygdala, hippocampus, and subthalamic nucleus 
with the adjacent substantia nigra. The brain specimens were fixed in 
10 % buffered formalin for an additional week and then embedded in 
paraffin. The 7-µm-thick sections were cut from formalin-fixed, 
paraffin-embedded blocks. All sections were routinely stained by 
applying hematoxylin-eosin (HE).   
In study V, the tissue microarray technique (TMA) was used. The 
HE stained slides of 7-μm thick sections were used to select regions for 
the core samples to be embedded into the TMA blocks. Each core 
sample measured 2.0 mm in diameter as recommended by Kauppinen 
and colleagues (Kauppinen et al., 2006). The core tissue samples from 
the donor blocks were taken using Beecher Instrument’s Manual Tissue 
Arrayer 1 instrument and each core sample was inserted into 
previously made holes into the wax surface of the recipient block. The 
maximum depth of the punch used was 8 mm, and the thickness of the 
recipient block was 10 mm. The resulting TMA blocks were warmed in 
an oven for 10 minutes at 57 °C to promote the adherence of the core 
sample to the paraffin of the recipient block. Finally, the TMA blocks 
were placed upside-down in stainless steel molds for cooling.  
In studies I, III and IV cerebrovascular microscopically detectable 
lesions in gray matter were estimated in HE stained slides and the 
extent of vascular lesions was graded on a three step scale 0-no vascular 
lesions found, 1 - only microscopic and 2- both microscopic and 
macroscopic vascular lesions detected. Microscopically detectable 
lesion included lacunar lesion and small infacrts. The features of CVLs 
are given in study I, figure 2. In study I, II, III and IV AD-related lesions 
were classified into 7 stages (0-VI) as proposed by the guidelines 
established by Braak and Braak and for staging the modified 
Bielschowsky silver impregnation technique and as well HPτ IHC were 
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applied (Braak and Braak, 1991; Braak et al., 2006).  In studies II and IV, 
the distribution of αS pathology was categorized into 7 stages (0-6) 
according to the scheme recommended by Braak and co-workers (Braak 
et al., 2003).  
 
4.4 BRAIN REGIONS EXAMINED 
 
As Thal and co-workers have demonstrated, the Aβ deposition are 
usually first seen in the cortical regions, indicating that cortex is the 
most vulnerable region for Aβ deposition (Thal et al., 2002).  In studies 
III and IV, the objective was to evaluate the influence of proposed risk 
factors on the accumulation of Aβ in a large study cohort, and thus the 
accumulation of Aβ was assessed in the most susceptible regions 
i.e.cortical regions. In study I, the purpose was to test the proposed 
hypothesis that focal cerebral ischemia could lead to the aggregation of 
extracellular Aβ in thalamic nuclei at least in rats, and thus Aβ IR was 
assessed in the thalamus and in the watershed area i.e. parietal cortex 
which is also one of the predisposes regions for the accumulation of Aβ. 
In study II, Aβ deposition was evaluated in cortex and striatum because 
these have been reported to be vulnerable regions both for Aβ 
deposition and αS pathology, and especially in LB disorders, there is 
claimed to be an extensive burden of αS pathology in the striatum. 
 
Table 1.  The Aβ immunoreactivity was evaluated in the following 
brain areas in each study 
Brain area Study I Study II Study III Study IV 
Frontal cortex   X  
Gingulate cortex    X 
Temporal cortex  X X X 
Parietal cortex X X X X 
Striatum  X   
Thalamus X    
 
 
4.5 IMMUNOHISTOCHEMISTRY 
 
Aβ, HPτ and αS were visualized using immunohistochemical (IHC) 
methodology. The sections were deparaffinized and rehydrated 
according to the standard procedure. Following the pretreatment, the 
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sections were incubated with non-immune serum for 30 min at room 
temperature to eliminate nonspecific reactions. After the epitope 
unmasking procedures, the antibody was applied. The antibodies, 
dilutions and pretreatments are given in Table 2. The sections were 
incubated overnight at 4 °C. On the following day, the sections were 
incubated with biotinylated second antibody for 30 min followed by 
streptavidin enzyme conjugate (LABSA Zymed laboratories, South San 
Francisco, CA) for 30 min at room temperature. The presence of the 
streptavidin biotin complex was visualized using VectorRed (Vector 
Laboratories, Burlingame, CA), romulin 3-amino-9-ethyl carbazole, or 
diaminobenzidine. All immunostained sections were counterstained 
with Harris' haematoxylin, dehydrated, and mounted in DePex.  
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Table 2. Antibodies, pretreatments and dilutions 
Name Source, code Clone Pretreatment Dilution 
Hyperphosphorylated 
τ 
Innogenetics, 
BR-03 
AT8 none 1:500 
α-Synuclein Novocastra, 
NCL-ASYN 
KM51 autoclave + 80% 
FA, 5 min 
1:1000 
Amyloid-β Dako, M0872 6F/3D 80 % FA, 6 h 1:100 
Amyloid-β 40 Invitrogen, 44-
348 
polyclonal 80 % FA, 6 h 1:1000 
Amyloid-β 42 Invitrogen, 44-
344 
polyclonal 80 % FA, 6 h 1:1000 
Amyloid-β  Immuno-
Biological 
Laboratories, 
10323 
82E1 * 1:1000 
Amyloid-β Signet, 9320 6E10 * 1:2000 
Amyloid-β Signet, 9220 4G8 * 1:2000 
Amyloid-β 42 Signet 12F4 * 1:1000 
Amyloid precursor 
protein A4 
Chemicon, 
MAB348 
22C11 * 1:100 
Amyloid precursor 
protein 
Novocastra , 
NCL-APP 
40.10 * 1:40 
Amyloid precursor 
protein C-terminal 
Sigma , A8717 polyclonal * 1:1000 
 
*The following antigen retrieval methods were applied: 80% formic 
acid for 2, 10, 60 minutes and for 6 hours or microwave in citrate buffer 
pH 6.0 for 3 x 5 minutes or a combination of microwave in citrate buffer 
pH 6.0 for 3 x5 min and 80 % formic acid for 10 minutes 
 
4.6 SEMIQUANTITATIVE ASSESSMENT 
 
The presence of Aβ, HPτ and αS was assessed blinded to the clinical 
data. The Aβ score, used in study I, was based on the number of stained 
extracellular aggregates in the total microscopic field (x100 
magnification). The numbers of aggregates were semiquantitatively 
assessed on a scale from 0 to 3 and the final score, ranging from 0 - 3 for 
each subject, was obtained by calculating the average of scores obtained 
in the two most affected areas. In studies III and IV, a computer-
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assisted image analysis, the NIH image system for PC, was used in the 
quantification of Aβ expression. The Aβ labeling was estimated in all 
three neocortical sections. In each neocortical section, the assessment 
was carried out in three randomly selected fields of gray matter with 
light microscopy at x40 magnification. The load of Aβ was given as 
mean stained area fraction in frontal, temporal and parietal cortices 
(Kraszpulski et al. 1998). 
 
4.7 STATISTICAL ANALYSIS 
 
SPSS for Windows program was used for the statistical analyse. In 
studies I, II and IV, the relationships between various clinical and 
pathological parameters were assessed by adjusted logistic regression. 
The strength of association was estimated by the odds ratio, and this is 
presented with the 95% confidence interval. Furthermore, the non-
parametric Mann-Whitney U-test was used to assess differences 
between study groups. In study III, also Kruskal-Wallis and χ2 tests 
were applied and further the correlations between different variables 
were tested by the non-parametric Spearman’s correlation test. The 
level of significance was p<0.05 in all analyses. 
 
4.8 ETHICAL ASPECTS 
 
The study has been autohorized by the ethics committee of Kuopio 
University Hospital and in study IV a permission for sampling of the 
analyzed brain material was granted by the National Board of 
Medicolegal affairs in Finland 3485/(32/200/98). 
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5 Results 
 
5.1 INFLUENCE OF ANTIBODY AND ANTIGEN RETRIEVAL METHOD 
ON THE STAINING OF EXTRACELLULAR Aβ (V) 
 
The influence of Ab and antigen retrieval method on the staining 
results is demonstrated in Table 3. The extracellular staining of Aβ 
deposits was excellent with all commercial Abs directed to the amino 
acid residues present in Aβ (82E1, 6E10, 6F3D, 4G8, Aβ40, Aβ42, 12F4) 
irrespective of the antigen retrieval method. The fleecy/diffuse 
aggregates were seen to the same extent, independent of which 
commercial Aβ Ab was used.  Formic acid treatment enhanced the 
intensity of extracellular IR and the contrast increased with up to 60 
minutes of formic acid pretreatment. The combination of boiling in a 
microwave oven for 3x 5 min in citrate buffer and incubation in 80% 
formic acid for 10 min intensified the extracellular labeling but the 
concomitant increase in the background IR decreased the contrast. If 
the antigen retrieval method was restricted to only boiling in a 
microwave oven, this led to an overall weaker IR staining of the 
extracellular deposits. 
Antibodies directed to APP or its derivatives (APP C-terminal, 
APP40.10) did not label the extracellular aggregates in any specimens. 
 
Table 3. Influence of antibody and antigen retrieval method on the 
staining results in cognitively intact subjects 
Im
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a
c
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v
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Antigen retrieval method 
80 % formic acid for 2,10, 
60 min or 6 h 
Microwaving in citrate 
buffer pH 6.0 3 x 5 min 
Microwaving in citrate 
buffer pH 6.0 3 x 5 min+ 
80% formic acid for 10 min 
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light gray = no immunoreactivity was detected, dark gray = 
immunoreactivity was detected, e-extracellular immunoreactivity, i-
intracellular immunoreactivity 
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5.2 GENERAL CLINICAL CHARACTERISTIC OF THE STUDY 
POPULATION (I-IV) 
 
The demographic of study population is given in table 4. The inclusion 
criteria for each study were different and since study cohorts may 
include same subjects, the study groups are not directly comparable 
with each other.  The gender distribution was rather equal in studies I-
III, whereas in study IV, most cases were male. The oldest mean age at 
death was 77 years in study II where the inclusion criterion was the 
presence of αS pathology, whereas the mean age at death was lowest in 
study IV. All cases with clinical signs of dementia were excluded from 
studies I and IV, and further all cases displaying Braak stage V-VI were 
also omitted from study I to ensure that none of the cases had full 
blown dementia. The highest prevalence of dementia was seen in 
subjects who also displayed αS pathology (study II).   
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5.3 GENERAL PATHOLOGICAL CHARACTERISTIC OF THE STUDY 
POPULATION (I-IV) 
 
The Braak stage and the prevalence of Aβ in the neocortex in different 
study cohorts are given in table 4. Most cases were in Braak stage 0-II, 
even in study II which included subjects with αS pathology. Overall, 
the prevalence of cortical Aβ varied from 19% to 60% in the different 
study groups. In studies III and IV, the prevalence of Aβ was assessed 
only in the neocortex.  In study I, 14 % and in study II, 19 % of subjects 
displayed extracellular Aβ deposits only in the cortical regions 
corresponding to Aβ phases 1-2. In study I, Aβ deposits were detected 
in 19 % of the subjects in the thalamus and parietal cortex representing 
Aβ phase 3 or over. Interestingly, 5 % of subjects exhibited Aβ in the 
thalamus but not in the parietal cortex. In study II, 41 % of subjects 
displayed both neocortical and striatal Aβ deposits representing Aβ 
phase 3 or over, whereas 2 % of subjects had only striatal Aβ deposits. 
 
5.4 INFLUENCE OF AGE AND GENDER ON THE PREVALENCE OF Aβ (I-
IV) 
 
In all study cohorts, the prevalence of Aβ deposition in the cortex was 
associated with age at death (logistic regression, p<0.05). The 
association between gender and the prevalence of Aβ IR varied in the 
different study cohorts. In study I, no association between gender and 
Aβ IR could be found, whereas in studies II and III, a statistical 
significant association was found and a higher odds ratio for female 
subjects was estimated (logistic regression, p <0.05). In study III, when 
adjusted for age, the association between gender and the prevalence of 
Aβ disappeared, whereas in study II, the association remained 
statistically significant (p=0.03).  In study IV, a tendency toward a 
higher odds ratio was noted for female subjects but the value was not 
statistically significant (p>0.05).  
 
5.5 INFLUENCE OF CVL ON THE PREVALENCE OF Aβ DEPOSITION (I) 
 
In study I, where the influence of CVL on the accumulation of 
extracellular Aβ was assessed, 35 % of subjects with CVL and 25 % of 
controls displayed extracellular Aβ deposits in the parietal cortex. Aβ 
deposition in the thalamus was detected in 25 % of subjects with CVL 
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and 21 % of control subjects. The load of Aβ in the parietal cortex and 
thalamus did not significantly differ between controls and subjects with 
CVL. Even after adjusting for age, there was no association between 
CVL and the load of Aβ. However, a tendency toward higher odds 
ratios for Aβ deposits, though not statistically significant, was noted in 
subjects with acute CVL (logistic regression).  
 
5.6 INFLUENCE OF DIADETES ON THE PREVALENCE OF Aβ 
DEPOSITION (III) 
 
In study III, 60 % of diabetics and non-diabetics displayed Aβ in the 
neocortex. The load of Aβ in the brain was not influenced by 
hyperglycemia when comparing diabetics to non-diabetics. The load of 
Aβ was significantly higher in subjects carrying the APOE allele ε4 
when compared subjects with the other APOE alleles but this finding 
was not influenced by diabetes (χ2, p<0.001).  
 
5.7 INFLUENCE OF ALCOHOL ABUSE ON THE PREVALENCE OF Aβ 
DEPOSITION (IV) 
 
In study IV, cortical extracellular Aβ deposits were seen in 19 % of 
subjects. Aβ deposits were equally seen in heavy alcohol consumers, 
referring an alcohol intake of more than 300 grams of ethanol per week, 
and control subjects. To evaluate further the influence of alcohol abuse 
on the accumulation of extracellular Aβ, regression analysis was used 
to control for confounding factors such as gender and age. Even when 
adjusted for age and gender, the load of extracellular Aβ did not differ 
between the groups (p>0.05).  
 
5.8 RELATIONSHIP BETWEEN Aβ PATHOLOGY AND CONCOMITANT 
HPτ AND αS PATHOLOGY (I-IV) 
 
The prevalence of co-existence of Aβ and HPτ pathology is given in 
table 5. The prevalence of AD-related HPτ pathology varied extensively 
between the different study cohorts, ranging from 33 % to 83 %. The 
prevalence was highest (83%) in study II which included subjects with 
αS pathology and the oldest mean age at death. The prevalence was 
lowest (33%) in study IV that had the youngest mean age at death. 
There was a strong association between the age at death and the extent 
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of HPτ pathology in all study cohorts (Kruskal Wallis test, p=0.001). As 
seen in table 5, HPτ and Aβ pathology often co-existed. The prevalence 
of cortical Aβ deposits increased in parallel with increasing Braak stage 
in all four study cohorts. When adjusted for age, there was a significant 
association between Braak stage and the prevalence of Aβ deposits in 
the cortex (logistic regression analysis, p<0.05).  
 
Table 5. The co-existence of Aβ and HPτ pathology in different study 
cohorts 
Braak stage The prevalence of cortical Aβ deposits, % 
Study I Study II Study III Study IV 
0 20  20  31  8  
I-II 45  53  61  38  
III-IV 78  97  89   
V-VI  100 100 50  
All 34  60  60  19  
 
In study II, all subjects displayed αS IR in the amygdaloid complex 
or/and in the substantia nigra and in 52 % of subjects αS IR was also 
seen in the cortical regions. Moreover, 35 % of subjects displayed both 
Aβ and αS pathologies in the neocortex. All three pathologies, αS, Aβ 
and HPτ, were detected in 53 % of subjects. In study III, 16 % of subjects 
displayed αS IR in the midbrain and all 3 pathologies were seen in 10 % 
of subjects. In study IV, αS was detected in 3 % of subjects and 2 % of 
subjects displayed all three pathologies.  
 
5.9 INTRACELLULAR STAINING (V) 
 
The influence of antibody and antigen retrieval method on the staining 
results is given in table 3. In study V, intracellular labeling could be 
observed with three of seven Abs directed to the amino acid residues 
present in Aβ (82E1, 6E10, 4G8) already at the age of two years and the 
IR remained high in all samples over the entire age range of 2 to 100 
years. With the mAb 4G8, intracellular labeling was seen irrespective of 
the antigen retrieval method, but with mAbs 6E10 and 82E1 
intracellular labeling was detected only when the combination of heat 
and formic acid was applied. With Abs Aβ40, Aβ42 and 12F4, which 
are directed to Aβ neoepitopes, intracellular labeling was only detected 
in AD cases, regardless of which antigen retrieval method was utilized. 
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Interestingly, with the mAb 6F3D, intracellular labeling was not 
detected in any of the specimens under any conditions. 
Antibodies directed to APP or its derivatives (APP C-terminal, 
APP40.10) detected intracellular labeling regardless of the antigen 
retrieval method. 
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6 Discussion 
 
6.1 THE STRENGHTS AND LIMITATIONS OF THE STUDY 
 
The present study has several strengths but also some limitations which 
are due to methodological aspects. When assessing material from 
human subjects, a major limitation is the variable of the material due to 
many factors such as genetic variation, systemic diseases, medications 
and various environmental factors. The study cohort was selected from 
the eastern Finnish population. The Finnish population is unique in that 
it originates from a small number of founders, and therefore the genetic 
variation is smaller than in most other populations. On the other hand, 
due to the special nature of the population, any results may be limited 
merely to this population.  The study cohort was selected from the 
subjects who underwent an autopsy including an examination of the 
brain, and thus bias in the sample, due to selection for autopsy, is 
possible. Therefore, the results may not be generalized to the entire 
population. However, the study population included approximately 8 
% of all deceased and it included both symptomatic and unimpaired 
individuals who had been living in the area of eastern Finland over the 
ten years that the survey encompassed, and therefore it is fairly 
representative (Tilastokeskus).  The strength of the present study lies in 
a large study cohort and its sampling strategy, as the selection of 
material was based on the presence of a pathological finding regardless 
of the clinical phenotype.   
The use of human post-mortem tissue also gives rise some 
methodological problems. Agonal and post-mortem events may 
influence the staining results obtained. In study V, the mode of death 
i.e. agonal events, did not seem to alter the amount of Aβ IR. Post-
mortem delay (PM) and fixation time may have an impact on staining 
results, however, it has been shown that variations in PM have no 
qualitative effect on the staining patterns (Kuusisto et al., 2003) and 
recently it was shown that good Aβ IR was obtained even after 14 years 
of fixation (Pikkarainen et al., 2010). In order to minimize the variability 
attributable to the methodology, all Aβ stainings were carried out 
manually, the staining procedures were standardized and positive 
control sections were always used. The specificity of immunodetection 
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was ensured by using well-characterized and widely used commercial 
Abs such as AT8 and 6F3D.  
The weakness of this study is its retrospective nature. Only cases 
with adequate clinical information were included. Most cases had been 
examined by a neurologist and nearly everyone had at least visited a 
general physician at a maximum of one year before death.  Some cases 
classified as cognitively intact might have displayed mild cognitive 
impairment that had not been recognized during their lifetime. 
However, it is unlikely that the presence of moderate or full-blown 
dementia would have been overlooked. It has been evaluated that 
approximately 4 % of Finnish population have undiagnosed type 2 DM, 
and therefore some cases classified as non-diabetics might have had 
DM (Diabetesliitto). Also, reliable information on the duration of 
diabetes in study III was not available. In study IV, the information of 
alcohol consumption was collected retrospectively, which includes the 
possibility of misclassification. 
In study I the load of Aβ was semiquantitatively assessed, whereas 
in study III and IV the computer based NIH Image system was used to 
quantification of Aβ. However, it has been shown in an inter-laboratory 
study that the quantification of Aβ deposits is not reliable, and thus a 
dichotomous assessment is recommended if one wishes to achieve 
reproducible results (Alafuzoff et al., 2008). 
 
6.2 INFLUENCE OF ANTIBODY AND ANTIGEN RETRIEVAL METHOD 
ON THE STAINING RESULTS (V) 
 
Immunohistochemistry is a widely used method to visualize Aβ in the 
brain and it has been shown that antigen retrieval method is significant 
with respect to the staining results (Alafuzoff et al., 2008; Beach et al., 
2008; Christensen et al., 2009; D'Andrea et al., 2003; Ohyagi et al., 2007; 
Sheng et al., 2003). In study V, it was shown that all commercial Abs 
stained extracellular Aβ deposition excellently irrespective of which 
antigen retrieval method was used. The extracellular accumulation of 
Aβ was visualized by applying mAb 6F3D in studies I-IV. The mAb 
6F3D labels the extracellular deposits excellently and the positivity was 
easily identified because of the excellent contrast. Six hours’ incubation 
in formic acid was used as an antigen retrieval method, because it has 
been shown to be the optimal pretreatment strategy for visualization of 
Aβ deposits (Kraszpulski et al., 1998).  However, in study V, we 
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showed that after 60 minutes of formic acid pretreatment the contrast 
no longer increased suggesting that 60 minutes of formic acid treatment 
is enough to visualize extracellular Aβ aggregates.  
In contrast to the extracellular labeling, the intracellular labeling was 
strongly dependent on the choice of Ab and antigen retrieval method. 
With Aβ Abs 4G8, 6E10 and 82E1 intracellular staining was detected in 
all cases irrespective of disease or age and the staining was already seen 
at the age of two years.  The amino acid sequence that is recognized by 
clones such as 4G8, 6E10 and 82E1 is also found in the full-length APP, 
and thus these Abs fail to distinguish Aβ from APP (Horikoshi et al., 
2004; Knobloch et al., 2007; LeBlanc et al., 1996; Lord et al., 2006). 
Intracellular staining was seen with Abs directed to the C-terminus of 
Aβ such as Aβ40, Aβ42 and 12F4, which have been reported to be 
specific for Aβ, only in the AD cases with widespread neuronal 
degeneration. The lack of intracellular immunoreactivity in unimpaired 
subjects may be due to its absence or that there are such low levels of 
the protein to be undetectable at light microscopic level by 
immunohistochemistry method. If only the Abs against the N- terminus 
or the mid-portion of Aβ had been applied, the conclusion would have 
been that the intracellular accumulation of Aβ is seen in all cases 
irrespective of age or condition. On the contrary, if only those Abs 
directed to the C-terminus of Aβ had been used, the conclusion would 
have been that the intracellular Aβ would only have been present in the 
brains of subjects with AD. These results emphasize that the staining 
results and their interpretation are strongly dependent on the choice of 
Ab. 
Furthermore, the intracellular staining with Abs 6E10 and 82E1 was 
only detected when the sections were both heated and incubated in 
formic acid indicating that, in addition to the choice of Ab, the antigen 
retrieval method is significant. These results indicate that multiple Abs 
including Abs directed to the N- and C-terminal neoepitopes should be 
used when assessing the presence of intracellular Aβ and the influence 
of antigen retrieval method should be borne in mind.     
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6.3 IMPACT OF AGE AND GENDER ON THE EXTRACELLULAR 
ACCUMULATION OF Aβ (I-IV) 
 
Age is the best-known risk factor for neurodegenerative diseases 
(Fratiglioni et al., 2000; Lobo et al., 2000). In the present study, a strong 
association was found between age and the prevalence of Aβ pathology 
in all study cohorts. The presence of cortical Aβ deposits in cognitively 
intact subjects varied from 19 % in study IV to 45 % in study II. This 
variation is mainly due to the differing inclusion criteria, as in study IV, 
the mean age at death was lowest, whereas in study II, the mean age at 
death was highest and all subjects also displayed αS pathology which 
has been reported to enhance the aggregation of Aβ (Jensen et al., 1997; 
Masliah et al., 2001). Therefore, it is not surprising that the prevalence 
of Aβ was highest in study II. In population based studies, the 
prevalence of cortical Aβ in non-demented subjects has varied from 33 
% to 59 % (Bennett et al., 2006; Knopman et al., 2003; MRC CFAS, 2001). 
The mean age at death in these studies was over 80 years. These 
prevalence figures are rather similar to those found here. As shown in 
these studies, a substantial proportion of the elderly non-demented 
subjects display Aβ in the neocortex (Bennett et al., 2006; Knopman et 
al., 2003; MRC CFAS, 2001). The increase in the prevalence of cortical 
Aβ with age supports the hypothesis that the elimination of Aβ may be 
insufficient in elderly population leading to the accumulation of Aβ 
with age.  
Current studies suggest that female gender is a risk factor for AD, 
however, in some studies, the difference between men and women has 
been age dependent (Fratiglioni et al., 2000; Lobo et al., 2000). In this 
study, the role of gender was not entirely clear, as in study I no 
association was found between gender and the accumulation of Aβ but 
in studies II-IV, a higher odds ratio for female gender was found. When 
adjusted for age only in study II, the association between gender and 
the prevalence of Aβ was found indicating that the accumulation of Aβ 
is age rather than gender dependent.  
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6.4 THE EVOLUTION OF EXTRACELLULAR Aβ DEPOSITIONS (I-II) 
 
Thal and colleagues proposed the evolution of Aβ deposition in the 
brain follows a distinct sequence in which the regions are hierarchically 
involved (Thal et al., 2002). The majority of our cases (studies I and II) 
exhibited Aβ deposition only in the neocortex representing Aβ phase I-
II. However, some of the cases displayed a different pattern in the 
regional distribution of Aβ. In study I, 5 % of cases displayed Aβ 
deposits in the thalamus but not in the parietal cortex and in study II, in 
2 % of cases Aβ deposits were seen in the striatum but not in the 
neocortex. Thus, the evolution of Aβ does not invariably seem to follow 
the described phases. On the other hand, we did not assess the Aβ 
immunoreactivity systematically in all brain areas, and thus we were 
able to classify the subjects only into two groups according to the 
evolution of Aβ deposition.  Moreover, in study II, Aβ deposits were 
more often detected from the striatum in demented than cognitively 
intact subjects indicating a significance of striatal involvement in 
dementia. In line with this already in 1999 in the Nun study, a 
significance of striatal involvement in the early phase of AD was 
emphasized (Wolf et al., 1999). More recently, it was reported that in 
the PS1 mutation carriers, the accumulation of Aβ appeared to begin in 
the striatum while using PIB PET to visualize the amyloid (Bacskai et 
al., 2007; Klunk et al., 2004; Klunk et al., 2007). However, since the 
majority of the cases followed the described Aβ phases, it seems that 
concomitant pathology i.e. CVD, αS or some kind of genetic 
predisposition, may be responsible for the differing evolution of Aβ 
deposition.   
 
6.5 IMPACT OF CVL ON THE Aβ PATHOLOGY (I) 
 
It has been proposed that ischemic brain damage may induce the 
accumulation of Aβ in the human brain, and in animal studies the 
deposition of Aβ has been detected after occlusion of the middle 
cerebral artery in rats (Jendroska et al., 1995; van Groen et al., 2005). In 
study I, no association between the presence of CVL and Aβ deposition 
could be found. This finding is in agreement with other human post-
mortem studies (Honig et al., 2005; Mastaglia et al., 2003). However, a 
tendency towards a higher odds ratio for A deposition was noted for 
subjects with acute rather than chronic CVL, though this was not 
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statistically significant. This would support the hypothesis that Aβ 
represents an acute phase protein produced in a stress situation and 
which will be normally eliminated with time. This finding is in line 
with an animal study where Aβ deposits were seen in the surrounding 
of acute infarcts but the deposits vanished within a few weeks (van 
Groen et al., 2005; Hiltunen et al., 2009). It has further been shown in 
rats that focal cerebral ischemia in the cortex causes permanent 
aggregation of Aβ in the thalamus and this has been suggested to result 
in corticothalamic degeneration, alteration in APP trafficking, 
processing, and Aβ degradation in the thalamus (van Groen et al., 2005; 
HIltunen et al., 2009). In study I, the hypothesis that CVL induces the 
accumulation of Aβ in the thalamus was not corroborated as there were 
no differences in the amounts of Aβ in the thalamus when CVL subjects 
were compared to controls. The discrepant results may be due to 
physiological and anatomical differences between animals and humans 
(Harding et al., 1997; Rouiller and Welker, 2000). It has been shown that 
morphology of corticothalamic projections diverge between rats and 
monkeys, and thus it can be expected that these projections also differ 
between rodents and humans (Rouiller and Welker, 2000). 
Furthermore, the transcriptor factors for gene expression has been 
shown to diverge between humans and rodents (Odom et al., 2007) 
A second hypothesis is that CVL may cause functional changes in 
the cerebral blood vessels and in this way may influence the 
perivascular elimination route and consequently lead to the 
accumulation of Aβ (Pluta et al., 1999). If this assumption were to be 
correct, it would be predicted that subjects with chronic CVL would 
display more Aβ than subjects with acute CVL. The load of Aβ 
increased with age but this phenomenon was not influenced by CVL. 
This result indicates that it is diffuse age related changes in the walls of 
blood vessels or perivascular elimination route rather than CVL which 
results in the insufficient elimination of Aβ. In study I the purpose was 
to evaluate the proposed hypothesis that a focal ischemia leads to the 
accumulation of Aβ in the thalamus, and therefore the accumulation of 
Aβ was only evaluated in the thalamus and parietal cortex. With our 
study design it was not possible to evaluate the influence of small 
vessel disease on the accumulation of Aβ. The white matter lesions 
frequently seen in patients with VCI were neither evaluated. The 
association between small vessel disease, and Aβ load remains to be 
elucidated in the future studies.  
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6.6 THE ASSOCIATION BETWEEN Aβ PATHOLOGY AND DIABETES 
(III) 
 
Epidemiological studies have proposed that there is an association 
between AD and DM, however neuropathological studies have so far 
failed to detect any associations between AD-related pathology, such as 
Aβ deposits and NFTs, and DM (Arvanitakis et al., 2004; Arvanitakis et 
al., 2006; Heitner and Dickson, 1997; Janson et al., 2004; Leibson et al., 
1997; Ott et al., 1999; Peila et al., 2002). In the prospective Framingham 
clinical study, DM did not increase the risk for incidental AD (n=2210) 
(Akomolafe et al., 2006). In study III, in agreement with previous 
studies no association was found between AD-related pathology and 
DM, and thus the hypothesis is not supported that DM would elevate 
the load of Aβ by influencing the clearance of Aβ from the brain.  
Diabetes is a well-known risk factor for peripheral vascular 
pathology, and it may be assumed that the vessels are the primary 
target also in the brain, and thus it seems more likely that it is the 
microvascular changes that are responsible for the cognitive 
impairment rather than AD-related pathology in demented diabetics.   
 
6.7 THE RELATIONSHIP BETWEEN Aβ PATHOLOGY AND ALCOHOL 
ABUSE (IV) 
 
Numerous epidemiological studies have described the U-shaped 
relationship between alcohol intake and dementia, but the actual 
association between alcohol intake and neurodegenerative lesions is 
unclear (Huang et al., 2002; Marmot and Brunner, 1991; Ruitenberg et 
al., 2002).  In study IV, when evaluating 108 post-mortem brains alcohol 
intake did not have any influence on the extent of Aβ deposition. In 
agreement with our results, Freund and Ballinger reported already in 
1992 that NP counts were not increased in the brains of alcoholics.  In 
2002, Lahiri and colleagues demonstrated that alcohol may influence 
the processing of APP and an abnormal level of APP may lead to 
increased cleavage of Aβ.  It could be anticipated that if alcohol 
consumption were to increase the level of APP, the load of Aβ would 
be increased in the brains of alcoholics as compared to non-alcoholics. 
However, we did not find any statistically significant association 
between the occurrence and load of Aβ and alcohol intake and thus 
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heavy and chronic alcohol consumption does not seem to stimulate the 
production of Aβ nor does it diminish the elimination of Aβ or 
influence the accumulation of Aβ. 
 
6.8 SYNERGISTIC EFFECT OF Aβ, HPτ AND αS PATHOLOGY (I-IV) 
 
A large majority of older individuals have brain pathology and those 
with dementia most commonly have multiple brain pathologies 
(Schneider et al., 2007). Therefore, numerous studies have tried to 
unravel the complex relationship between all three pathologies i.e. Aβ, 
HPτ and αS and there has been an intense debate about which Aβ or 
HPτ pathology is the initiator of AD pathology.  In study II, Aβ 
deposits became more common in both the neocortex and striatum in 
parallel with the increasing severity of HPτ pathology and similarly in 
studies I, III and IV, the prevalence of Aβ deposits correlated with 
Braak stage. These findings support the assumption that the Aβ phase 
correlates with Braak stage and that Aβ and HPτ may be linked (Hardy 
and Selkoe, 2002; Thal et al., 2002).  Since only half of the cases in Braak 
stage I-II displayed cortical Aβ corresponding to Aβ phase I-II this 
indicates that the formation of HPτ is not necessarily secondary to Aβ 
deposition. Even though these pathologies often co-exist, it does not 
necessarily indicate that one is caused by other and this proposal is also 
supported by the fact that the spatial distribution of Aβ and HPτ is 
different and that HPτ pathology may precede cortical Aβ pathology by 
decades (Braak and Braak, 1991; Delacourte et al., 2002). These findings 
support the hypothesis that Aβ and HPτ are independent but they may 
have synergistic effects once they co-occur, as was demonstrated in 
experiments with mice carrying mutations in tau and APP which 
developed more abundant HPτ pathology in those brain areas that 
were expressing both APP and tau in comparison to those areas which 
expressed only tau (Delacourte et al., 2002; Lewis et al., 2001; Zhou et 
al., 2006).  
Numerous studies have reported the very high incidence of 
concomitant HP and S pathologies (Hamilton, 2000; Uchikado et al., 
2006; Wakisaka et al., 2003). Accordingly, in study II where all subjects 
displayed αS pathology at least in the substantia nigra or/and in the 
amygdaloid complex, 83 % of cases displayed HPτ pathology and 60 % 
displayed also cortical Aβ deposition. There is compelling evidence to 
suggest that all three pathologies can affect each other directly or 
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indirectly and the interaction of these pathologies may explain how 
dementia develops (Mandavilli, 2006; Masliah et al., 2001).  
Recently, abnormal intracellular accumulation of TAR-DNA-binding 
protein (TDP-43) has been reported in AD and DLB (Amador-Ortiz et 
al., 2007). TDP-43 is a major component of the tau negative and 
ubiquitin positive inclusions and is the hallmark lesion of 
frontotemporal lobar degeneration and amyotrophic lateral sclerosis 
(Arai et al., 2006). Furthermore, it has been suggested that the co-
occurrence of TDP-43 in AD and DLB might contribute to 
neurodegeneration or modify the clinical course (Arai et al., 2009; 
Pikkarainen et al., 2009). Taken together, the existence of one pathology 
may lower brain reserve capacity against other pathological events and 
the co-occurrence of pathologies may lower the threshold of pathology 
required to evoke clinical dementia (Schneider et al., 2007). In the 
elderly population, all three pathologies often co-exist, and thus it is 
important to evaluate all pathological changes before the significance of 
any lesions in relation to clinical symptoms can be assessed.  
 
6.9 THE PATHOGENIC ROLE OF Aβ 
 
The pathogenic role of extracellular Aβ has been controversial as the 
load of extracellular Aβ does not correlate with the severity of cognitive 
impairment and the majority of elderly population display extracellular 
Aβ as was also confirmed in the present study (Bennet et al., 2006; 
Jellinger, 2006b; MRC CFAS, 2001; Tyas et al., 2007). Moreover, the 
finding that the removal of Aβ plaques is not sufficient to stop the 
progressive neurodegeneration challenges the importance of Aβ in the 
pathogenesis of AD (Holmes et al., 2008).  Again, it is possible that the 
presence of Aβ plaques might be necessary to initiate the process but 
not to maintain it once it has started. There is an increasing body of 
evidence against the pathogenic role of extracellular Aβ and thus, the 
Aβ hypothesis was modified in 2004 (Wirths et al., 2004).  In the 
modified Aβ cascade hypothesis the accumulation of intraneuronal Aβ 
is a trigger for the cascade leading to neuronal death (Wirths et al., 
2004). Intraneuronal Aβ has been reported to be detectable in the first 
year of life, its level increases in childhood and remains high 
throughout adulthood even in healthy brains, and thus it is likely that it 
has a physiological function (Wegiel et al., 2007). However, most 
studies reporting the presence of intracellular Aβ are based on IHC and 
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Abs such as 4G8, 6E10 and 82E1 which do not distinguish Aβ from APP 
or its derivates, and thus it is possible that the intracellular labeling is 
APP rather than Aβ. APP is widely expressed in the brain and it has 
physiological functions. In study V, intracellular labeling was only 
detected in the brains of those AD subjects who also displayed severe 
HPτ pathology when this was visualized with Abs directed to 
neoepitopes. This finding could be interpreted to mean that 
intracellular Aβ can be seen only when the neuronal function is already 
damaged which challenges the role of Aβ as an initiator of the 
pathological cascade.   
It has been reported that the amount of soluble Aβ rather than 
insoluble Aβ correlates better with the severity of cognitive impairment 
suggesting that soluble Aβ may be the trigger (Figure 5.) (Lue et al., 
1999; McLean et al., 1999; Wang et al., 1999). Furthermore, it has been 
argued that intraneuronal Aβ must exist in a distinct assembly state for 
it to induce pathological alterations, as in vivo studies it has been 
demonstrated that soluble oligomers but not monomers can inhibit 
hippocampal LTP and alter memory function (Selkoe, 2008; Walsh et 
al., 2002; Walsh et al., 2002). 
Not only in AD but also in many neurodegenerative disorders has 
the formation of insoluble inclusions been considered to be responsible 
for synaptic dysfunction and neuronal cell loss. However, recent 
evidence indicates that these deposits may function as a reservoir and 
may be either inert or even protective (Baglioni et al., 2006; Haass and 
Selkoe, 2007).  It is possible that Aβ is produced as a compensatory 
response to the disease. Immunization may even increase the 
concentration of oligomeric Aβ during the active phase of 
disintegration, and therefore the process of removing Aβ might be 
harmful (Holmes et al., 2008). At present, there has been no systematic 
evaluation of the prevalence of Aβ in the human brain with Abs 
directed to Aβ oligomers. 
Our findings question the assumption that Aβ deposition is the 
initiator of the pathological cascade leading to neuronal death, however 
the present series of studies are descriptive in character, and thus no 
firm conclusions about the function of Aβ can be made. The role and 
the toxicity of Aβ remain to be determined.  
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Figure 5.  Molecular pathogenesis of AD (Modified from Jellinger 2006) 
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6.10 FUTURE ASPECTS 
 
Despite considerable progress in AD research, there are many issues 
that still need to be clarified. The role of extracellular Aβ deposition is 
still open. It is still unclear whether Aβ deposits are harmful, inert, or 
protective. Also, the role of intracellular Aβ need be clarified and 
especially the presence of intracellular Aβ in different diseases applying 
Abs specific for Aβ should be assessed. In addition to the role of Aβ 
deposits the co-existence of intra- and extracellular Aβ needs to be 
evaluated and whether or not there is a connection between 
intracellular Aβ and HPτ pathology. The influence of small vessel 
disease on the accumulation of Aβ needs to be clarified. Furthermore, 
hyperinsulinemia has been reported to be linked with Aβ via IDE. IDE 
degrades pancreatic amylin as well as extracellular Aβ, and thus the 
level of pancreatic amylin should be compared to the level of 
extracellular Aβ.  
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7 Conclusions 
 
Epidemiological and animal studies have pointed to a connection 
between the accumulation of Aβ and CVD, DM, and alcohol abuse. 
However, in the present series of studies, no statistically significant 
association was found between the occurrence and load of extracellular 
Aβ and these putative risk factors. The following conclusions can be 
made: 
 
1. CVL does not influence the load of extracellular Aβ in the 
 thalamus and parietal cortex.  
 
2.  All three pathologies: Aβ, HPτ, and αS, often co-exist in the 
elderly population. They can occur independently but once they 
co-exist, they may have synergistic effects. Furthermore, the 
presence of one pathology may lower brain reserve capacity to 
withstand a second or third pathology.  
 
3.  DM does not elevate the load of extracellular Aβ. 
 
4.  Heavy and chronic alcohol intake does not influence the 
accumulation of extracellular Aβ, HPτ, or αS pathology.  
 
5.  When IHC is applied to visualize Aβ, especially intracellular Aβ, 
the staining results and the conclusions will depend strongly on 
the chosen antibody and the pretreatment strategy, and thus 
multiple antibodies should be used when assessing the 
intracellular accumulation of Aβ. 
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Deposition of amyloid-β (Aβ) is 
considered to be a key element in the 
pathogenesis of Alzheimer’s disease 
(AD). In this study no association 
between Aβ deposition and cere-
brovascular disease, diabetes, alco-
hol abuse and synucleinopathy was 
found, a finding that is at odds with 
proposal that these alterations are 
risk factor for AD via Aβ deposition. 
The strong association between age 
and Aβ deposition indicates that the 
age-related changes are significant 
for the accumulation of Aβ. The role 
of Aβ deposits remains open - are 
they harmful, inert, or protective? 
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